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ABSTRACT 
 
The innate immune receptors, toll-like receptor-2 (Tlr2) and toll-like receptor-4 
(Tlr4), are implicated in the development of inflammation and insulin resistance in various 
cell populations. However, little is known about the relationship of these receptors in diet-
induced obesity (DIO). We have shown that Tlr4 deficient C57BL/10ScN mice were 
protected against DIO, specifically when mice were fed a high saturated fatty acid (SFA) 
diet. Moreover, these mice exhibited a specific reduction in adipose tissue (AT) 
inflammation as evidenced by the reduction in nuclear factor kappa B (NFκB) activation, 
proinflammatory gene expression, and macrophage accumulation. There was also a marked 
increase in Tlr2 expression in mice fed a high fat diet. 3T3-L1 adipocytes treated with the 
Tlr2 agonist, zymosan A (ZymA), exhibited increased NFκB and activator protein-1 (AP-1) 
activation, proinflammatory gene expression, reactive oxygen species (ROS) accumulation, 
and insulin resistance, similarly to palmitate or Tlr4 agonist lipopolysaccharide (LPS). These 
effects were attenuated in adipocytes treated with a specific c-jun N-terminal kinase (JNK) 
inhibitor (SP600125) indicating involvement of this intracellular kinase in SFA and Tlr 
agonist-mediated signaling. Finally, we demonstrated that Tlr2-/- mice were also protected 
from DIO. However, unlike Tlr4 deficient 10ScN mice there were no significant changes in 
body weight, energy intake, or lipid profile. Inflammatory and oxidative stress markers in 
serum (C-reactive protein (CRP), endotoxin, and monocyte chemoattractant protein-1(MCP-
1)) and AT (Tumor necrosis factorα (TNFα), interleukin-6 (IL-6), MCP-1, F4/80, and nitric 
oxide synthase-2 (NOS2) transcript abundance) were attenuated in Tlr2-/- and 10ScN mice, 
which was more apparent in mice fed high SFA diet. Insulin sensitivity was improved in 
10ScN, but not Tlr2-/- mice. However, stromal vascular (SV) cells isolated from AT of Tlr2-/- 
 vii 
 
mice had a marked increase in insulin sensitivity, demonstrating the potential involvement of 
Tlr2 in obesity-induced insulin resistance in AT. Based on these studies, Tlr2 and Tlr4 may 
represent ideal targets for pharmaceutical, as well as dietary, interventions designed to 
attenuate obesity and related co-morbidities, including Type 2 diabetes mellitus (DM) and 
cardiovascular disease (CVD).  
1 
 
CHAPTER 1.  GENERAL INTRODUCTION 
 
Introduction 
Currently, approximately 60 million adults in the U.S. are classified as obese (BMI > 30), 
and equally alarming, the prevalence of obesity has increased 30% during the past decade 
(1). The medical and economic implications of obesity are exacerbated by its co-morbidities, 
which include diabetes mellitus (DM) and atherosclerotic cardiovascular disease (CVD). 
Generally, a chronic inflammatory state develops in association with obesity, and likely 
contributes to the development of insulin resistance and its progression to DM (2,3). This 
chronic inflammation associated with obesity is evident by the increased concentrations of 
circulating proinflammatory cytokines, including tumor necrosis factorα (TNFα) and 
interleukin-6 (IL-6) (4,5). The exact mechanisms which regulate this inflammation are not 
yet clearly defined, but recent evidence has unequivocally implicated the adipocyte and its 
inflammatory pathways as pivotal factors in the development of insulin resistance (6,7).  
Several genetic and diet-induced rodent models of obesity have revealed that obesity 
promotes increased expression of proinflammatory cytokines in adipose tissue (AT) (2,8), 
and that this may be mediated by activation of nuclear factor kappa B (NFĸB) or activator 
protein-1 (AP-1) signaling pathways (9,10). Furthermore, obesity-linked inflammation 
parallels changes in adipose cell populations and phenotypes as AT is expanded through 
hyperplasia and hypertrophy. Excessive adipocyte hypertrophy initiates changes in the 
inflammatory characteristics of the adipocyte that include greater NFĸB transcriptional 
activity and increased expression of proinflammatory cytokines (11). Excessive adipocyte 
hypertrophy has also been associated with increased cell death and recruitment of 
macrophages to AT (6,7). Macrophage infiltration represents a major contributor to obesity-
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induced inflammation and is partially regulated by the chemokine, monocyte chemoattractant 
protein-1 (MCP-1) (12,13), which is known to be increased in the circulation of obese 
subjects (14).  
Furthermore, innate immunity may be a primary mediator of obesity-induced 
inflammation in AT. Toll-like receptors (Tlrs) represent key innate immune receptors that are 
expressed in adipocytes, preadipocytes, and macrophages (15-17). Interestingly, both Tlr2 
and Tlr4 expression are increased with obesity and DM (16). Collectively, recent findings 
indicate lipopolysaccharide (LPS)-stimulated Tlr4 activation induces expression of TNFα, 
IL-6, and MCP-1 in adipocytes and preadipocytes through a NFκB dependent pathway 
(15,18,19). LPS also increased Tlr2 transcript abundance in adipocytes (20). The interaction 
between the LPS molecule and Tlr4 is mediated through the lipid A component of LPS, 
which consists of several fatty acids attached to a phosphate and a central glucosamine dimer 
(21). The fact that fatty acids can directly interact with Tlr receptors and stimulate 
downstream signaling pathways that lead to inflammation is therefore not surprising (Figure 
1). Palmitate and other saturated fatty acids (SFA) clearly stimulate proinflammatory 
cytokine expression and NFκB activation in adipocytes (22).  
Several recent investigations (23-25) have provided evidence linking obesity-induced 
inflammation to fatty acid signaling through Tlr4. Shi and colleagues (25) have shown that 
Tlr4-/- mice have improved insulin sensitivity and attenuated inflammatory markers in AT 
when stimulated with either lipid infusion or a high fat diet (25). These data are further 
supported by in vitro experiments in which free fatty acid (FFA)-induced inflammatory 
responses in adipocytes are attenuated when Tlr4 signaling is blunted by siRNA strategies. 
More recently, Lee et al. (26) observed that SFA, but not polyunsaturated fatty acids 
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(PUFA), activated Tlr2 dimerization and activatied stress-linked kinases, such as NFκB and 
AP-1, in RAW264.7 macrophages. Thomas and colleagues (27) also demonstrated that the 
Tlr2 ligand, Zymosan-A (ZymA), when administered at low doses in vivo, stimulated chronic 
low grade inflammation contributing to the formation of new adipocytes.  These studies 
underscore the important link between obesity and innate immunity, and how dietary SFA 
may exacerbate obesity and its related co-morbidities through direct interactions with Tlr2 
and Tlr4 in AT. The significance of the current studies is that it will identify the involment of 
Tlr2 and Tlr4 in obesity-induced inflammation. Moreover, elucidation of AT’s role in Tlr-
mediated inflammation and insulin resistance. 
 
Objectives and Specific Aims 
 
Our goal is to elucidate the specific mechanisms by which SFA induce insulin 
resistance in adipocytes in relation to obesity and diabetes. Our central hypothesis is that 
SFA exacerbate obesity-induced inflammation and insulin resistance through interactions 
with not only Tlr4, but also through Tlr2, and that the SFA signaling through Tlr2 also 
culminates in activation of proinflammatory transcription factors NFκB and AP-1 in AT. The 
rationale for the work proposed herein is that understanding the relationship between innate 
immunity and obesity will allow recommendations for specific prevention and intervention 
strategies, and future recommendations directed at optimizing human nutrition and health 
and thereby reducing the risk of diseases associated with obesity.  The Specific Aims are: (i) 
to determine whether Tlr2-/- and/or Tlr4-/- mice are protected against high fat diet-induced 
obesity, inflammation, and insulin resistance, (ii) to determine involvement of Tlr2 and/or 
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Tlr4 signaling in adipocyte inflammation and insulin resistance, and (iii) to determine the 
ability of specific dietary fatty acids to induce inflammation through Tlr2 and/or Tlr4. 
 
 
 
 
 
 
Figure 1. Fatty acid signaling through Tlr2 and Tlr4 in adipocytes. Our proposed 
mechanism of action of Tlr2 and Tlr4 mediated inflammation in adipocytes. Activation of 
Tlrs requires stimulation by respective ligands, which include SFA. Following ligand binding 
an inflammatory signaling cascade is initiated resulting in activation of proinflammatory 
transcription factors, NFκB and AP-1. The subsequent increase in transcription leads to the 
release of proinflammatory mediators, which can act in an autocrine (e.g. adipocyte), 
paracrine (e.g. adipocytes, macrophages, endothelial cells, and other AT-based cells), and 
endocrine (e.g. muscle and liver tissue) manner. 
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CHAPTER 2.  REVIEW OF LITERATURE 
 
 
Obesity and Diabetes: Role of Inflammation and Oxidative Stress 
Obesity Prevalence and Implications 
Over the past few decades the prevalence of obesity has risen dramatically 
worldwide. According to the Center for Disease Control, more than 20 states had obesity 
prevalence rates greater than 25% in 2006. Data from the 2003-2004 National Health and 
Nutrition Examination Survey (NHANES)  reported the prevalence rates of obesity in 
adolescents and adults were 17.1% and 32.1%, respectively (28). These data indicate a 3% 
increase in obesity from 1999-2000.  
Factors related to obesity include socioeconomic status (SES), education, ethnicity, 
and gender with interactions among these factors. For instance, African Americans and 
Mexican Americans show greater obesity prevalence with reduced SES, whereas this 
relationship is not evident in Asian Americans (29). Regardless of these distinctions among 
ethnic groups, there appears to be a significant rise in obesity independent of SES. Moreover, 
the trend is expected to continue with obesity prevalence possibly reaching 35%, 36%, 33%, 
and 55% by 2010 among white men, white women, black men, and black women, 
respectively (30).  
 Obesity is a major health concern in the U.S., as well as in the majority of developed 
countries. Individuals with a high BMI (>35) are estimated to have a significant reduction in 
life span, especially in younger adults (31). In white males, this reduction in life span 
approaches 22%. The increased mortality rates observed with obesity may be due to its 
associated co-morbidities, including DM, CVD, hypertension (HTN), and dyslipidemia. 
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Severely obese adults (BMI >40) exhibit 7.38 times greater risk of developing DM, 6.38 
times greater risk of developing HTN, and 1.88 times greater risk of developing dyslipidemia 
as compared to healthy weight adults (BMI 18.5-24.9) (32). Furthermore, the prevalence 
rates of DM have closely paralleled the increase in obesity. According to the CDC, the 
number of individuals diagnosed with DM in the U.S. has increased from 5.6 million in 1980 
to 15.8 million in 2005 independent of age, gender, and ethnicity. The majority of this 
increase is associated with the increased prevalence of obesity.  
 The impact of obesity and related co-morbidities on society includes not only the 
health consequences, but the financial burden. From 1987 to 2001, the health care costs in 
the U.S. have risen dramatically. Obese individuals account for 27% of this inflation, 
whereas 38% of health care spending is attributed to DM (33). In 2002, obesity-attributable 
medical costs approached 93 billion dollars, half of which was paid through Medicaid and 
Medicare (34). The financial burden of obesity and DM also affects private companies and 
businesses. For instance, although only 3% of an employee population is classified as obese, 
it accounts for 21% of total medical costs primarily through increased disability and 
absenteeism (35). Of all obesity related co-morbidities, DM represents the largest burden to 
the health care system. The American Diabetes Association (ADA) reported that in 2002, the 
direct (medical care and services) and indirect (disability and premature death) costs were 
over 132 billion dollars. However, it has been demonstrated that these costs can be greatly 
reduced with the advent of prevention vs. treatment programs targeted at addressing obesity 
before it manifests into DM or other co-morbidities (36). 
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Metabolic Syndrome and Insulin Resistance 
 
 Investigations regarding the relationship between obesity and DM have revealed a 
clustering of biological abnormalities known to precede the development of chronic DM. 
Referred to as the metabolic syndrome (MS), this cluster of abnormalities involves several 
obesity-related complications, including HTN, dyslipidemia, glucose intolerance, and central 
adiposity (Figure 2). The Third Report of the National Cholesterol Education Program  
 
 
Figure 2. Development of Metabolic Syndrome (MS). The development of MS is preceeded 
by central adiposity. The primary defects appear to be insulin resistance with concominant 
hyperinsulinemia. When untreated these aberrations can mediate several risk factors 
(including glucose intolerance, dyslipidemia, and inflammation) that lead to chronic disease, 
such as Type 2 DM and CVD. 
 
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 
(ATP III) defines MS as three or more of the following criteria: abdominal obesity (waist 
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circumference >102 cm in men and >88 cm in women); hypertriglyceridemia (1.69 mmol/L); 
low high-density lipoprotein (HDL) cholesterol (1.04 and 1.29 mmol/L in men and women, 
respectively); HTN (systolic blood pressure >130 and diastolic blood pressure >85 mm/Hg); 
impaired glucose tolerance (IGT) (6.1 mmol/L). Based on these criteria, estimate indicate 
that > 20% of U.S. adults have MS, which translates to more than 47 million Americans (37).  
Substantial evidence now indicates that insulin resistance may be the primary defect 
contributing to the development of IGT, dyslipidemia, and HTN. Previous investigations (38) 
indicated that prevalence rates for insulin resistance in subjects with IGT,  
hypercholesterolemia, hypertriglyceridemia, and HTN ranged from 54 to 88%. Furthermore, 
the prevalence of insulin resistance in subjects exhibiting a combination of glucose 
intolerance, dyslipidemia, and hypertension was 95.2% (38).  Insulin resistance, defined as 
reduced sensitivity to the action of insulin, is associated with impaired glucose uptake in 
peripheral tissues, particularly in skeletal muscle (39,40). The condition is also frequently 
accompanied by an increase in insulin secretion from pancreatic cells. This compensatory 
mechanism enables β-cells to maintain euglycemia through increasing circulating insulin 
concentration. When hyperinsulinemia can no longer compensate for increased insulin 
resistance, aberrations in glucose metabolism occur and eventually progress to DM (39,40).  
Abdominal obesity appears to be a major mediator of insulin resistance and hyperinsulinemia 
(41,42). Older, insulin resistant subjects exhibit greater accumulation of AT in the abdominal 
region. This centralized distribution of AT is associated with a significant reduction in 
insulin sensitivity (41). Additionally, obese postmenopausal women (body fat >45%) 
exhibiting preserved insulin sensitivity have nearly 50% lower visceral AT (VAT) compared 
to gender, age, and body fat-matched insulin resistant subjects (43). Accumulation of VAT is 
  12
also associated with the development of MS in normal weight, overweight, and obese elderly 
men and women (44). The role of subcutaneous AT (SAT) in the pathogenesis of insulin 
resistance and MS is less pronounced than that of VAT (45). In a review of 23 intervention 
strategies (46), VAT loss in response to diet, drug, and exercise intervention represented the 
highest percentage of weight loss than all other AT depots. This may be due to various 
genetic and physiological differences between depots. Vohl et al (47), reported that in 
severely obese subjects (BMI 45-81) nearly 350 genes were differentially regulated between 
VAT and SAT. Furthermore, VAT has been shown to be more lipolytic and catecholamine 
sensitive, as well as more insulin resistant, than SAT (48). These studies indicate that in 
addition to overall obesity, the distribution of AT is an important factor in the development 
of insulin resistance and MS. 
Inflammation and Insulin Resistance 
 
There is considerable evidence that inflammation is a primary mediator of obesity-
related co-morbidities, including DM and CVD (49-56). Additionally, several studies have 
demonstrated that inflammation is an integral factor in the development of MS in several 
populations (52-54,56). Ishikawa, et al (52) reported that circulating C-reactive protein 
(CRP) concentrations, a common clinical indicator of systemic inflammation, was 
significantly higher in Japanese men and women diagnosed with MS than their non-affected 
counterparts. In this population, the odds ratio for having MS was also greatest in individuals 
categorized in the highest tertile of CRP (52). Data from the Insulin Resistance 
Atherosclerosis Study (IRAS) (49) confirmed that chronic subclinical inflammation, as 
indicated by increased CRP, is associated with dyslipidemia, central adiposity, HTN, and 
insulin resistance. These findings are consistent in African-American, Hispanic, and White 
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Non-Hispanic populations.  Increased CRP levels are also associated with higher age-
adjusted risks for developing DM, even after adjusting for presence of CVD, SES, physical 
activity, alcohol consumption, smoking, and family history of DM (54). In subjects with DM, 
the underlying aberration contributing to the development of insulin resistance appears to be 
a subclinical inflammatory state marked by increased concentrations of circulating 
leukocytes, fibrinogen, and CRP (55). Inflammation is also associated in the pathogenesis of 
CVD (50,51,57). Results from the Cardiovascular Health Study (57) indicated that in adults 
(>65) with atherosclerosis in combination with increased CRP had a 72% greater risk for 
CVD-related death. This risk can be exacerbated in subjects diagnosed with DM, suggesting 
an even greater incidence of CVD-related mortality in patients with both inflammation and 
DM (58).  
A novel approach for the treatment of DM and CVD is the use of anti-inflammatory 
medications. Non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, have long 
been used for their ability to reduce blood glucose (59-61). The exact mechanism is not fully 
understood, but may be related to reduced FFA concentrations (59,62). One early 
investigation (63) demonstrated that ibuprofen reduced glucose concentration following a 
glucose challenge. This improvement in glycemic control was associated with a greater 
insulin response and reduced FFA (63). More recently, data from the Physicians' Health 
Study, a randomized, double-blind, placebo-controlled trial, indicated a 44% reduction in 
myocardial infarction with aspirin treatment compared to placebo (64).  The development of 
atherosclerotic CVD and stroke is increased in individuals with DM. However, the ability of 
NSAIDs to reduce CVD- related morbidity and mortality in diabetic individuals remains 
unclear (65). Data from the DECLARE-DIABETES Trial (66) indicated that aspirin in 
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combination with two other anti-inflammatory medications was able to lower cardiovascular 
related complications in diabetic patients.  Hundal and colleagues (67,68) observed that two 
weeks of aspirin treatment improved insulin sensitivity and the lipid profile in male and 
female diabetics. This improvement may be mediated in part by reduced IκB kinase β (IKKβ) 
activation (68), which is the upstream activator of the proinflammatory transcription factor, 
NFκB. Activation of IKKβ, either in obese mice or IKKβ agonist treated Fao hepatoma cells, 
resulted in reduced insulin signaling which was reversed by NSAID treatment (68). Overall, 
these studies indicate that treatment of inflammation improves obesity-related complications, 
including insulin resistance and dyslipidemia, which are major risk factors for CVD and DM. 
Cytokine and Chemokine-Induced Insulin Resistance 
 
IL-6. Proinflammatory cytokines, such as IL-6 and TNFα, are small proinflammatory 
proteins that are increased with obesity (4,5,69). The importance of IL-6 in obesity-induced 
inflammation is demonstrated by identification of single nucleotide polymorphisms (SNP) in 
the IL-6 promoter (70-73). Fernandez-Real et al. (71) identified a SNP in the 5’ flanking 
region of the IL-6 gene at position -174 in which a guanine was replaced by a cytosine. This 
SNP was associated with reduced plasma IL-6, as well as lower circulating insulin, TAG, 
and FFA in healthy subjects. This SNP was further associated with greater insulin sensitivity 
and glycemic control, as well as a reduced WBC (70). Alternatively, Kubaszek and 
colleagues (72), found this IL-6 SNP to be associated with reduced energy expenditure (EE), 
basal metabolic rate (BMR), whole body glucose uptake, and glucose oxidation in a healthy 
Finnish population (72). These findings were further supported by a recent study (73) that 
indicated this SNP is associated with higher risk of developing obesity-related metabolic 
disorders, including insulin resistance.  
  15
Despite the discrepancy in SNP associated phenotypes, it is evident that increased 
circulating IL-6 is associated with obesity related co-morbidities. Data from the Health, 
Aging and Body Composition Study (74) indicated the odds ratio of developing subclinical 
CVD was greatest in the tertile of patients with the highest concentration of serum IL-6. 
Additionally, Bahrami, et al (75) suggested that serum IL-6 was the strongest predictor of 
obesity-associated coronary heart disease. Recent data from the Monitoring of Trends and 
Determinants in Cardiovascular Disease (MONICA)/Cooperative Research in the Region of 
Augsburg (KORA) study also indicated that both high IL-6 and CRP concentrations are 
associated with the development of DM (76). Furthermore, elevated IL-6 concentrations is 
associated with increased mortality in elderly adults (77). The impact of IL-6 on obesity-
related co-morbidities may be dependent on the development of insulin resistance. Rush, et 
al (78) observed that IL-6 concentrations is positively associated with reduced β-cell function 
and insulin resistance in a population of Asian Indian immigrants. Furthermore, obese 
adolescents exhibited insulin resistance attributed to elevated IL-6 (79).  
IL-6 involvement in insulin resistance may be mediated through impairment of 
insulin signaling (80-83). Chronic IL-6 administration has been shown to inhibit insulin 
signaling in adipocytes, muscle, and liver (82-84). Specifically, IL-6 was observed to inhibit 
autophosphorylation of the insulin receptor (IR) and downstream effectors including insulin 
receptor substrate-1/2 (IRS-1/2), phosphatidylinositol-3 kinase (PI3K), protein kinase-1 
(Akt/PKB), and glucose transporter-4 (GLUT4) (80-84). These effects were mediated 
through activation of specific proinflammatory signaling intermediates, such as suppressors 
of cytokine signaling-3 (SOCS3) (81,82,84) and protein kinase C (PKC) (82). Activation of 
SOCS1/3 inhibited tyrosine phosphorylation of the insulin receptor (81,85). Furthermore, 
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PKC activation increased serine phosphorylation of IRS-1/2 (82) and thus contributed to the 
development of IL-6-mediated insulin resistance. These data suggest that IL-6 may induce 
insulin resistance through multiple mechanisms including direct impairment of insulin 
signaling. 
TNFα. Hotamisligil et al. (4,86) originally proposed the involvement of the 
proinflammatory cytokine, TNFα, in obesity-associated insulin resistance. More recently, 
specific SNPs in the TNFα gene have been associated with DM (87-89). Moreover, certain 
SNPs predisposed diabetic patients to athertosclerotic-related complications (88). Fontaine-
Bisson et al. (89) identified a SNP in the TNFα promoter (-238G>A) that is associated with 
reduced FFA clearance and insulin resistance in obese subjects with DM but not in lean 
controls. Additionally, the same SNP was observed at a higher frequency in patients with 
coronary artery disease, especially in subjects with DM or HTN. Analysis of the TNFα gene 
and promoter indicates the importance of this cytokine in the regulation of obesity induced 
insulin resistance.  
Elevated TNFα levels are closely related to components of MS including, IGT, HTN, 
and dyslipidemia in obese adults (90) and adolescents (91). High serum TNFα levels are also 
associated with insulin resistance in elderly patients (92). Tam and colleagues (93) observed 
that neutralization of  TNFα with NSAIDs contributed to improved lipid profile and insulin 
sensitivity in subjects with rheumatoid arthritis.  
TNFα-mediated insulin resistance, as observed in obesity and DM, is suggested to 
involve impairment of insulin signaling. This may include reduced IR autophosphorylation, 
as well as decreased IRS-1/2 activation (94-96). The mechanism for reduced tyrosine 
phosphorylation is not fully characterized. However, it may involve activation of 
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phosphotyrosine phosphatase (PTPase) (96). Alternatively, TNFα is observed to increase 
serine phosphorylation of IR and IRS-1/2, thereby contributing to reduced insulin sensitivity 
(97-100). Serine phosphorylation of insulin signaling intermediates involves activation of 
downstream effectors, such as PKC or mitogen-activated protein kinases (MAPK), 
extracellular signal-regulated kinases (ERK) (99), c-Jun N-terminal kinases (JNK) (100), and 
p38-MAPK (97). However, the exact pathway involved appears to be tissue-specific. These 
data implicate TNFα as a major contributor to insulin resistance and further supports the idea 
that proinflammatory cytokines are involved in obesity-related co-morbidities. 
MCP-1. Chemokines are small proteins similar to cytokines, which also exhibit the 
ability to induce chemotaxis. Certain chemokines, such as MCP-1 and interleukin-8 (IL-8), 
promote migration of monocytes and neutrophils, respectively. Data from the Cooperative 
Health Research in the Region of Augsburg Survey identified serum chemokine 
concentrations as independent risk factors for DM (101). Moreover, MCP-1 concentration 
was associated with increased risk of CVD mortality in a 7-year longitudinal study (102). 
Recent work (103) has shown that a high concentration of circulating MCP-1 was associated 
with insulin resistance and DM. Several SNPs have been identified in the MCP-1 gene and 
promoter. Although there is still debate regarding the extent of the association, there is 
evidence to suggest that the A-2518G polymorphism in the distal regulatory region of MCP-
1 is associated with heart disease and myocardial infarction (104,105). In addition, the G/G 
genotype at position -2518 in the MCP-1 promoter was associated with lower plasma MCP-1 
and reduced prevalence of insulin resistance and DM (103). 
Obesity is associated with increased circulating MCP-1 (13,69). Overexpression of 
this chemokine or its corresponding receptor (CCR2) stimulated insulin resistance and 
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hepatic steatosis in several rodent models of obesity (12,106). Furthermore, multiple obese 
mouse models, either transgenic (TG) or diet-induced (DIO), exhibited elevated MCP-1, 
which was associated with greater macrophage accumulation into peripheral tissues, 
including AT (12,106). More recently, it was observed that in vivo infusion of chemokine 
stimulated adipogenesis in mice (107). This effect may account for the increased adiposity 
and FFA observed in TG-MCP-1 mice (12).  
There is limited evidence implicating the direct involvement of MCP-1 with insulin 
signaling. However, it appears that recruitment of macrophages into tissues important in 
glucose homeostasis, including the pancreas, liver, skeletal muscle, or AT, results in an 
inflammatory response that contributes to the development of insulin resistance. 
Additionally, MCP-1 involvement in oxidative stress and ROS formation represents another 
potential mechanism of chemokine-induced insulin resistance (108). Finally, increased MCP-
1 expression in pancreatic islets and beta-cells could result in β-cell dysfunction and thus 
promote IGT. Regardless of the mechanism, it is clear that increased MCP-1 expression is 
involved in the pathogenesis of obesity-related complications. 
ADN. Obesity is not only associated with increased proinflammatory cytokines and 
chemokines, but is also associated with reduced concentrations of anti-inflammatory 
proteins, such as adiponectin (ADN). Several genetic analyses (109,110) observed that a 
quantitative trait locus (QTL) on chromosome 3 (3q27), the site of  the ADN gene, was 
strongly correlated with insulin resistance, MS, and DM. Data from the Metabolic Risk 
Complications of Obesity Genes Project (109) indicated that chromosome 3 also had the 
highest association with BMI, waist circumference, and insulin sensitivity. Additional 
genetic analysis observed the presence of multiple SNP in the ADN gene associated with 
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increased risk of DM and CVD (111-115). More specifically, the G/G genotype at position 
276 in the ADN gene is associated with reduced ADN, as well as insulin resistance, DM, and 
CVD (111-113). Multiple investigations have since indicated that obesity is associated with 
dysregulation of ADN (116-118). Arita et al. (116) initially reported a negative correlation 
between BMI and plasma ADN in obese subjects. Furthermore, hypoadiponectinemia is 
associated with several components of MS, including insulin resistance, dyslipidemia, and 
inflammation (117,119,120). Xydakis and colleagues (120) demonstrated that obese 
individuals with MS had lower serum ADN compared to obese individuals without MS. 
Patients diagnosed with DM or CVD are also observed to have significantly lower plasma 
ADN (118,121,122). This is especially true for high risk populations, such as Pima Indians.  
ADN possesses key anti-inflammatory properties, which likely contribute to its 
varied metabolic effects. Plasma ADN was negatively correlated with CRP, IL-6, and TNFα 
in obese subjects (123,124). Furthermore, ADN attenuated LPS-induced IL-6 and TNFα 
expression in both macrophages and adipocytes (19,125,126). LPS-stimulated NFκB 
activation was also prevented with ADN treatment (22), which may explain the observed 
reduction in proinflammatory cytokines. Conversely, administration of  IL-6 or TNFα 
blunted ADN expression and secretion in 3T3-L1 adipocytes (127-129). Furthermore, 
monocyte proliferation and macrophage function, including phagocytic activity and cytokine 
release, were reduced by ADN (130,131). Foam cell formation, as determined by lower 
macrophage cholesteryl ester content and scavenger receptor expression, was also attenuated 
by ADN (132). These data indicate that ADN is a key anti-inflammatory mediator.  
Several studies have examined the role ADN plays in vivo.  Genetically engineered 
ADN knockout (KO) mice exhibited reduced insulin sensitivity in response to a high fat diet 
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(133-135). Maeda et al. (133) demonstrated that ADN deficient mice had impaired insulin 
signaling in skeletal muscle. Moreover, this effect was corrected by adenoviral produced 
ADN (133). Alternatively, Nawroki and colleagues (134) suggested that the reduction in 
insulin sensitivity in ADN KO mice was attributed to increased hepatic glucose production.  
Several additional studies (136,137) indicated the liver as the primary site of ADN action. 
These observed differences in the mechanism of action of ADN can be attributed to 
structural differences in the protein. ADN forms several distinct oligomeric complexes. 
These include a high molecular weight (HMW, >250 kDa), medium molecular weight 
(MMW or hexamer, ~180 kDa), and low molecular weight (LMW or trimer, ~90 kDa) 
species (138-141). Furthermore, a proteolytic cleavage product of ADN that includes the 
globular C-terminal of the protein (gADN) was also present in human plasma (142).  
In humans, females have a greater proportion of HMW and hexamer complexes than 
males (138-140). Additionally, BMI is negatively correlated with the concentration of HMW 
species, but not the hexamer or trimer forms (139). Pajvani and colleagues (138) reported 
that lower HMW to total ADN was associated with lower insulin sensitivity in diabetic 
subjects. Furthermore, use of insulin sensitizing drugs, such as thiazolidinedione (TZD), 
increased HMW but not total ADN in these subjects (138). The HMW species is suggested to 
improve hepatic insulin sensitivity (138,141). Wang et al. (141) demonstrated the HMW 
species stimulated 5'AMP-activated protein kinase (AMPK) in liver, which lead to inhibition 
of gluconeogenic enzymes, phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6-
phosphatase (G6Pase). Alternatively, gADN was associated with skeletal muscle insulin 
sensitivity in obese and diabetic humans (143,144) and rodents (142,145-147). Bruce and 
colleagues (144) observed that gADN in vitro stimulated glucose uptake and FA oxidation in 
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skeletal biopsies from lean and obese subjects. This effect was attributed to increased AMPK 
and acetyl-CoA carboxylase (ACC) activation. Administration of gADN also increased IR 
and IRS-1 activation, as well as glucose uptake in primary rat adipocytes (148). 
Oxidative Stress and Insulin Resistance 
 
 ROS are small, highly reactive molecules possessing oxidative abilities primarily 
attributed to an unpaired electron. Examples include superoxide anion (O2-), hydrogen 
peroxide (H2O2), hydroxyl radical (•OH), and nitric oxide (NO•) (149). These molecules play 
important roles in cell signaling. However, accumulation of ROS can contribute to oxidation 
of amino acid side chains, protein-protein cross-links, and protein fragmentation (149).  
Oxidative stress is implicated in the pathogenesis of multiple diseases (150). Several 
investigations have indicated a role of oxidative damage in atherosclerosis (151), HTN (152), 
and DM (153). Obesity has also been linked to increased oxidative stress (154,155). Data 
from the Framingham Heart Study (155) indicated that urinary 8-epi-prostaglandin F2 alpha 
(8-epi-PGF2 alpha), an F2-isoprostane, a marker of ROS, formed via a noncyclooxygenase 
pathway, was positively associated with BMI and waist circumference in male and female 
subjects. Moreover, for every 5 kg/m2 of BMI there was a 9.9% increase in urinary 8-epi-
PGF2 concentration, indicating very high levels of oxidative stress. Furukawa et al. (154) 
also observed a positive correlation between BMI and urinary 8-epi-PGF2 in healthy 
Japanese men and women. Additionally, a positive association has been shown (154) 
between obesity and plasma thiobarbiturate reactive substances (TBARS), an end product of 
lipid peroxidation.   
Obesity-induced oxidative stress represents a potential link between obesity and its 
associated co-morbidities. Cardona and colleagues (156) reported that individuals with MS 
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exhibited increased markers of oxidative stress compared to patients without MS. This same 
group also demonstrated that antioxidant defense systems were impaired in healthy 
individuals following high fat feeding (157). The increased oxidative stress associated with 
obesity is specifically linked to the development of insulin resistance (158-160). Obese 
individuals diagnosed with DM exhibit increased oxidative stress and reduced antioxidative 
capacity compared to healthy controls (158). Mohora et al. (159) determined that obesity and 
DM were both associated with increased ROS, but obese subjects with DM exhibited a 
greater concentration of plasma malondialdehyde (MDA), a marker of oxidative stress. These 
findings are supported by additional groups (160) and clearly link oxidative stress as a bridge 
between obesity and DM. 
The mechanisms involved in oxidative stress-induced insulin resistance have not been 
fully elucidated. However, multiple studies indicated involvement of ROS accumulation in 
hepatocytes (161), skeletal muscle (162-164), and adipocytes (165-167). Kumashiro and 
colleagues (161) demonstrated that overexpression of the antioxidative enzyme, superoxide 
dismutase 1 (SOD1) in the liver of diabetic db/db mice reduced hepatic ROS accretion and 
improved insulin sensitivity. Additionally, Dokken and colleagues (163) observed that 
isolated rat skeletal muscle incubated with H2O2 significantly inhibited insulin-stimulated 
glucose transport and glycogen synthesis. Furthermore, a mineralocorticoid receptor 
antagonist prescribed to control blood pressure, spironolactone, attenuated ROS induced 
insulin resistance through increased phosphorylation of IRS-1, Akt/PKB, and GLUT4 in 
soleus muscle of insulin resistant rats (162).  
Recent evidence suggests that increased oxidative stress in skeletal muscle is 
secondary to changes in AT. Adipocytes themselves exhibited insulin resistance in response 
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to oxidative stress (165-167). Rudich et al. (165) showed that low grade oxidative stress 
results in impaired insulin-stimulated GLUT4 translocation and PI3K activation in 3T3-L1 
adipocytes. Furthermore, basal, but not insulin-stimulated, glucose uptake was increased 
along with GLUT1 expression in response to increased H2O2 content (165). Several 
additional studies (164,166,168) confirmed that an increase in basal glucose transport occurs 
in response to oxidative stress in adipocytes. Moreover, it appears that increased basal 
glucose uptake may exacerbate ROS accumulation and inflammatory signaling in adipocytes 
(169-172) through activation of NFκB and AP-1 (173). These studies clearly link adipocyte-
specific oxidative stress to the development of insulin resistance and therefore connect 
oxidative stress to the development of DM and related co-morbidities. 
Obesity-Induced Insulin Resistance: Role of Free Fatty Acids 
 
Overview of Fatty Acid Induced Insulin Resistance 
 
Multiple investigations have demonstrated an increase in circulating FFA in obese 
humans (174-177) and animals (178,179). This elevation in FFA is largely attributed to 
increased basal AT lipolysis (180-182). However, the antilipolytic effect of insulin may also 
be impaired in obesity (183,184).  Regardless of the exact mechanisms involved, increased 
FFA is associated with insulin resistance in obese individuals (185,186). Moreover, infusion 
of FFA in lean humans and rats stimulated insulin resistance (187,188). These data indicate 
that an increase in FFA represents a primary connection between obesity and insulin 
resistance.   
Obesity-related co-morbidities, including DM and CVD, have also been directly 
associated with increased FFA (189,190). A cross-sectional analysis of offspring from 
parents diagnosed with DM (191), reported that non-diabetic offspring had increased FFA 
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that predisposed them to the development of DM. Pima Indians with the highest 
concentration of FFA had a 2.3 fold greater risk of DM than individuals with the lowest 
concentration of FFA (192). Impaired postprandial FFA clearance is also linked to CVD in 
diabetic individuals (193). Carlsson and colleagues (194) observed that higher FFA were 
associated with greater risk of myocardial infarction and stroke. Other markers of CVD, 
including endothelial dysfunction, vascular smooth muscle cell proliferation, and HTN were 
also associated with increased FFA (194). Additional studies (90,174) have indicated that 
elevated FFA is associated with the development of several other components of the MS, 
including HTN and dyslipidemia.  
Insulin sensitivity can be improved by lowering FFA concentration. Studies using the 
hypolipidemic drug, acipimox, demonstrated that a reduction in FFA improved insulin 
sensitivity in obese and diabetic individuals (193,195,196). Santomauro et al. (196) reported 
that acipimox reduced plasma FFA by more than 60%, which improved insulin-stimulated 
glucose uptake by greater than 2-fold in obese subjects under euglycemic hyperinsulinemic 
clamp conditions. The peroxisome proliferator-activated receptor-alpha (PPARα) agonist, 
fenofibrate, is commonly used for treatment of dyslipidemia (197). Activation of PPARα  is 
suggested to increase β-oxidation, improve lipoprotein profiles, and reduce inflammation 
(197). Data from the Bezafibrate Prevention Study showed a near 10% reduction in CVD-
related mortality (198). Moreover, it has been observed that treatment with the PPARα 
agonist improved several additional complications of MS, including insulin resistance (198-
200). Haluzik and colleagues (201) demonstrated that 14 d of fenofibrate treatment reduced 
blood glucose, FFA, TAG, and insulin resistance in lipogenic, simple carbohydrate diet fed 
mice. However, the insulin-sensitizing response of fibrates in humans is limited, which may 
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be due to lower PPARα expression in liver and skeletal muscle (202). The ability of lipid-
lowering medication to effectively attenuate insulin resistance, as well as lower risk for 
developing DM and CVD, indicates that FFA are key mediators in obesity-related co-
morbidities. 
Substrate Competition and Non-Oxidative Fatty Acid Metabolism 
 
Accumulating evidence (185,186) supports the theory that disturbances in glucose 
metabolism are secondary to changes in FA metabolism. The exact mechanism of FFA-
induced insulin resistance has not been fully elucidated. However, Randle et al. (203) 
originally proposed that the insulin resistant properties of FA were mediated through direct 
inhibition of glucose metabolism. More specifically, as intermediates of FA and TAG 
synthesis, such as citrate and acetyl-CoA, accumulate in the cytosol of muscle cells, enzymes 
involved in glucose oxidation, such as phosphofructokinase-1 and pyruvate dehydrogenase 
complex, are inhibited. This in turn reduces insulin-stimulated glucose uptake and 
metabolism (204-207). Overall, researchers have suggested that increased FFA induces 
peripheral insulin resistance and stimulates an initial hyperinsulinemic state, but as DM 
develops, β-cell dysfunction occurs and insulin secretion can no longer compensate for 
elevated FFA and thus hyperglycemia becomes apparent. 
Elevated serum FFA concentration is toxic to cells. Increasing the concentration of 
lipid within non-adipose tissue, such as skeletal muscle, liver, and pancreatic β-cells, has a 
more profound effect on cellular metabolism than impairment of glucose metabolism. This is 
evident by the increased level of apoptosis in these tissues in response to lipid accumulation 
(208-210). Lipotoxicity, excess lipid accumulation in non-adipocytes, can contribute to 
obesity-mediated β-cell failure, non-alcoholic steatohepatitis (NASH), and skeletal muscle 
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insulin resistance (211). The consequences of lipotoxicity may be mediated through products 
of non-oxidative FA metabolism, such as diacylglycerol (DAG) and ceramide (209,211). The 
accumulation of long-chain fatty acyl-CoA (LCFA) in the cytoplasm of non-adipocytes has 
been associated with the synthesis of DAG and ceramide (208,209,212). This effect appeared 
to be more pronounced in response to SFA, such as palmitoyl-CoA, whereas PUFA appeared 
to be protective (213). The free radical, nitric oxide (NO) has also been correlated with 
ceramide concentration and may represent the link between the FA metabolites and β-cell 
apoptosis (209). In addition to the potential reduction of insulin synthesis, that DAG and 
ceramide have been shown directly to inhibit insulin signaling (208,214-216). This action 
may be mediated PKB and PI3K, which are key intermediates of insulin-mediated glucose 
uptake (208,214,215). More specifically, FA metabolites activate PKC (208) and protein 
phosphatase 2A (PP2A) (214), which are both shown to directly inhibit insulin-mediated 
GLUT4 translocation.  Proinflammatory cytokines, such as IL-6 and TNFα, have also been 
shown to increase synthesis of ceramide (208), as well as directly stimulate PKC activation 
(4,86). Therefore, the overall impact of non-oxidative FA metabolites on insulin resistance 
may be secondary to inflammation. 
Dietary Fatty Acids Play a Role in Inflammation 
 
Dietary FA can be both pro- and anti-inflammatory. SFA may be responsible for the 
increase in proinflammatory cytokines and chemokines observed with obesity and MS (217-
222).  The consumption of a Westernized diet high in refined grains, red meat, SFA, and 
hydrogenated fats has been positively related to several markers of inflammation, including 
CRP, serum amyloid A (SAA), and IL-6 (223). Aeberli et al. (220) reported that total dietary 
fat is associated with CRP and IL-6 in obese children. Moreover, SFA intake is specifically 
  27
linked to the development of inflammation in humans. Fernandez-Real et al. (224) reported 
that palmitic and myristic acid consumption were negatively correlated to plasma ADN and 
insulin sensitivity. Alternatively, consumption of either omega 3 FA (n-3 FA) or 
monounsaturated FA (MUFA) have been associated with reduced inflammation and 
improved insulin sensitivity (225-229). More specifically, Pischon and colleagues (226) 
reported intake of the n-3 FAs, eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA), were inversely associated with plasma concentrations of the soluble TNFα receptor 
(sTNF-R) and CRP. Data from the Nurses’ Health Study (225) demonstrated that EPA and 
DHA intake were also inversely related to CRP, IL-6, and several proinflammatory adhesion 
factors, including E-selectin, soluble intracellular adhesion molecule (sICAM-1), and soluble 
vascular adhesion molecule (sVCAM-1). Similar anti-inflammatory effects have been 
observed with consumption of a diet rich in MUFA (228,229). Fito et al. (228) observed that 
consumption of virgin olive oil reduced plasma IL-6 and CRP in patients diagnosed with 
coronary heart disease. Thus, substitution of dietary SFA or trans FA (TFA) with either n-3 
FA or MUFA may atenuate obesity-induced inflammation and reduce the risk of DM and 
CVD. 
The mechanism of SFA-induced inflammation and insulin resistance is not fully 
elucidated, but it is clear that certain SFAs stimulate a proinflammatory response in various 
cells and tissues. Palmitate and other medium chained SFA-induced proinflammatory gene 
expression in endothelial cells (230,231), hepatocytes (232),  myotubes (233,234), 
macrophages (11), and adipocytes (22,100,235). Elevated circulating palmitate was also 
positively correlated with increased plasma IL-6 (231) and negatively correlated with plasma 
ADN (224). Moreover, human coronary artery endothelial cells exhibited increased IL-6 
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mRNA and protein expression in response to palmitate treatment (231). This vascular 
inflammation can in turn contribute to development of atherosclerosis (50). SFA-induced 
inflammation has also been associated with development of NASH (236). Joshi-Barve et al. 
(232) reported that palmitate-induced IL-8 expression stimulated lipid accumulation and 
insulin resistance in cultured hepatocytes (232). These effects have been dramatically 
reversed by blocking cytokine production with neutralizing antibody, improving hepatic 
insulin sensitivity (237).   
Skeletal muscle accounts for over 80% of glucose uptake under insulin-stimulated 
conditions (238). Thus, skeletal muscle represents a major target of FA-induced 
inflammation and insulin resistance. SFAs, such as palmitate, increased IL-6 and TNFα 
expression in skeletal muscle cells and have been associated with reduced insulin sensitivity 
(233,234,239,240). Sinha and colleagues (234) demonstrated that palmitate treatment 
reduced insulin-stimulated glucose uptake, corresponding to a decrease in insulin-stimulated 
IRS-1, PI3K, and Akt/PKB phosphorylation in L6 myotubes. Furthermore, Jove et al. (240) 
reported that palmitate inhibited insulin-stimulated glucose uptake, as well as GLUT4 
expression, in C2C12 muscle cells. These studies and others (233,239,241-243) indicated 
that SFA-induced insulin resistance was mediated through activation of distinct 
inflammatory pathways involving extracellular signal-regulated kinases (ERK), JNKs, and 
p38 mitogen-activated protein kinases (MAPK). These proinflammatory pathways lead to 
activation of transcription factors, such as NFκB and AP-1 (232,244,245). Blocking MAPK 
kinase activity or expression through use of specific inhibitors or genetic knockdown 
attenuates FA-induced insulin resistance in muscle cells. Furthermore, inhibition of NFκB 
activation appears to be of primary importance in blocking palmitate-induced insulin 
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resistance (233,234,239-241). Weigert and colleagues (233) reported that the proteosome 
inhibitor, MG132, completely blocked palmitate-induced NFκB DNA binding and 
corresponding IL-6 production in human myotubes. This relationship in consistent with other 
NFκB inhibitors, including pyrrolidine dithiocarbamate (PDTC), SN50, and parthenolide 
(234,240,241).  
 The ability of FFA to induce inflammation and insulin resistance in liver and skeletal 
muscle suggests that disturbances in these tissues are dependent on interactions with 
adipocytes. Dietze et al. (246) observed that co-culture of human muscle cells with 
adipocytes dramatically reduced insulin signaling in myotubes. In vivo studies observed an 
accumulation of FFA in skeletal muscle with obesity (247,248). This ecotopic storage can 
then promote systemic insulin resistance (249,250). Boden and colleagues (251) suggested 
that insulin resistance occured in adipocytes prior to skeletal muscle. They provided evidence 
that reduced insulin sensitivity in adipocytes promoted greater lipolysis and reduced FFA 
uptake that consequently led to ecotopic fat storage. Moreover, increased FFA concentration 
directly contributed to insulin resistance in adipocytes. Several groups (11,22,100) 
demonstrated that FFA-induced proinflammatory cytokine and chemokine expression and 
impaired insulin signaling in adipocytes. Ajuwon et al. (22) reported that palmitate induced 
IL-6 expression and NFκB activation in 3T3-L1 adipocytes. FFA also increased TNFα and 
MCP-1 expression through activation of JNK- and NFκB-mediated pathways (11,100). In 
addition to FFA, the proinflammatory cytokines/chemokines secreted from adipocytes 
(referred to as adipokines) also contributed to insulin resistance in non-AT (11,100). The 
impact of adipocytes on inflammation and insulin resistance suggests that they represent a 
potential therapeutic target for treatment of obesity-related co-morbidities, such as DM.  
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Obesity-Induced Insulin Resistance: Role of Adipose Tissue 
 
Adipose Tissue Cellularity and Changes with Obesity 
 
 AT represents one of the most dynamic tissues in the human body. It can represent as 
little as 3% of total body weight in conditioned athletes to over 70% of total body weight in 
severely obese individuals (252). The cellular prolife of AT is highly variable and depends 
greatly on depot location, as well as multiple genetic and environmental factors. However, 
despite substantial intra- and inter-individual differences there is a basic organization to AT, 
which consists of mature adipocytes, fibroblast-like preadipocytes, endothelial cells, lymph 
nodes, and nerves (252,253).  Adipocytes represent the major cellular component of AT. 
There are two distinct classifications of adipocytes: the unilocular white adipocytes and 
multilocular brown adipocytes.  
White adipocytes contain a large lipid droplet composed primarily of TAG and 
cholesteryl esters, ranging in size from 20 to 200 µM in diameter. Moreover, they exhibit 
distinct endocrine, paracrine, and autocrine properties via expression and secretion of 
multiple proteins, such as leptin, ADN, IL-6, TNFα, and MCP-1. Adipocytes are also targets 
for various signaling molecules released from β-cells, macrophages, neurons, hepatocytes, 
and adipocytes themselves. Some of the adipocyte-specific receptors mediating this signaling 
include insulin, cytokine (i.e. IL-6 and TNFα), adrenergic/cholinergic, and lipoprotein 
receptors (254).  Therefore, it is clear that the physiological role of white adipocytes extends 
beyond simple energy storage and involves complex interactions with central and peripheral 
tissues in order to regulate energy metabolism and systemic homeostasis.     
Brown adipocytes have a slightly different morphology than white adipocytes. For 
instance, these cells are smaller (20 to 40 µM), contain multiple lipid droplets, have 
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pronounced nuclei and cytoplasm, as well as increased capillary density (255). Brown 
adipocytes also exhibit a greater number of mitochondria contributing to the trademark 
brown color. The major functional difference between the two cell populations is the role of 
brown adipocytes in thermogenesis. Briefly, FAs stored within brown adipocytes are quickly 
accessed by mitochondria and subsequently oxidized generating a proton gradient. Normally, 
this gradient is used for ATP synthesis, but in brown adipocytes the uniquely expressed 
protonophore, uncoupling protein 1 (UCP1), mediates disruption of the gradient causing the 
protons generated in FA oxidation to be dissipated as heat (256). In rodents, this process 
plays an important role in thermal regulation. Newborn infants also possess high levels of 
brown adipocytes in several adipose depots (255). However, in adult humans the amount of 
these cells is dramatically reduced and are found dispersed among white adipocytes. In lean 
adults, researchers have suggested that, on average, there is one brown adipocyte for every 
100 to 200 white adipocytes in VAT (257). Several studies (253,255) indicated that reduced 
sympathetic stimulation of these cells resulted in transdifferentiation of brown adipocytes 
into a phenotype similar to white adipocytes. Moreover, it appears that this process may be 
reversed by using β-adrenergic agonists (258). The ability of these two adipocyte populations 
to interchange phenotypes has important implications for health and disease. 
Adipose expansion involves both adipocyte hypertrophy (increase in cell size) and 
hyperplasia (increase in cell number). Hypertrophy and hyperplasia occur naturally in normal 
growth phases, as well as with obesity (discussed below) (259,260). Adipocyte hypertrophy 
requires positive energy balance that results in accumulation of TAG. However, adipocytes 
are limited in the amount of lipid that can be stored. Hence, hyperplasia represents an 
important means by which AT can expand. Also referred to as adipogenesis, hyperplasia 
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involves proliferation of fibroblast-like preadipocytes and their subsequent differentiation 
into mature adipocytes (252,261). Proliferation of preadipocytes entails mitotic replication to 
increase cell number. Alternatively, differentiation of preadipocytes requires cell cycle arrest, 
as well as distinct molecular and cellular modifications that mediate conversion of 
preadipocytes to spherical, lipid-filled mature adipocytes (253,260,262-264).  Generally, 
proliferation occurs prior to differentiation. However,  researchers have suggested that 
partially differentiated cells may still be capable of replication (260). In normal human 
growth and development, differentiation is controlled by the expression of several adipogenic 
transcription factors, transcriptional coactivators, and cell-cycle proteins designed to increase 
the lipogenic capacity of the cell (262,263). Two transcription factors, CCAAT/enhancer 
binding protein α (C/EBPα) and PPARγ, are essential to adipocyte differentiation. Following 
initiation of growth arrest, preadipocytes undergo at least one more round of DNA 
replication and cell doubling, often referred to as clonal expansion (263,265). During this 
process, adipogenic transcription factors upregulate genes involved in adipogenesis. 
Complete (or terminal) differentiation of adipocytes is associated with complete exit from 
cell cycle and an increased expression of adipocyte-specific genes and proteins, including 
leptin, ADN, and TNFα (263). 
Obesity is associated with significant increases in adipocyte hypertrophy and 
hyperplasia (252,263,266). In obesity, mature adipocytes reach their lipid storage capacity at 
an accelerated rate. This in turn contributes to increased hyperplasia. Regulation of 
adipogenesis is thought to be mediated through a paracrine mechanism in which hypertrophic 
adipocytes secrete growth factors in response to their expanding size (264). These growth 
factors, such as insulin-like growth factor (IGF), can then promote preadipocyte 
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differentiation and proliferation (267-269). Blocking of IGF-1 signaling with specific 
binding proteins attenuates obesity and implicates hyperplasia as a physiological mechanism 
contributing to obesity (270). Wang and colleagues (271) observed that mice lacking 
preadipocyte factor-1 (Pref-1), a known inhibitor of adipogenesis, exhibited increased 
adiposity, an effect that was reversed through transgenic overexpression of the preadipocyte 
marker. Moreover, use of synthetic inhibitors of adipogenesis is proposed as a potential 
treatment of  obesity and related co-morbidities (272).  Therefore, individuals with greater 
adipogenic potential may be predisposed to obesity (273).   
Obesity-Induced Changes in Adipose Tissue Fatty Acid Metabolism 
 
 TAG stored in AT originates from either dietary fat that is packaged into 
chylomicrons in enterocytes of the small intestine (post-prandial) or from endogenously 
produced TAG that is packaged into very low density lipoproteins (VLDL) in the liver (post-
absorptive) (274). Once in the circulation, these lipid rich lipoproteins deliver TAG and FA 
to peripheral tissues, including skeletal muscle and AT. Delivery of FFA to adipocytes 
requires hydrolysis of lipoprotein based TAG from chylomicrons and VLDL by lipoprotein 
lipase (LPL) (275) This process involves adipose-specific VLDL-receptor recognition of 
apoprotein E, located on VLDL and chylomicrons (276). LPL is initially synthesized in 
adipocytes and then exported to the luminal surface of capillary endothelium where it 
hydrolyses, with acylation stimulating protein (ASP), TAG to FFA and glycerol (277). 
Dysregulation of LPL, as observed in obesity has been associated with dyslipidemia and 
insulin resistance (275,278,279). Kitajima et al. (278) reported that systemically 
overexpressed LPL attenuated insulin resistance in obese rabbits. However, increased LPL 
activity in AT is associated with dyslipidemia and insulin resistance (279). The mechanism 
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underlying these differences is unclear, but may relate to the difference in the lipid oxidative 
activity of various tissues. 
Following hydrolysis of TAG from lipoproteins in the endothelial lumen, FFAs are 
transported through the plasma membrane of adipocytes by specific FA transporters, such as 
CD36 and fatty acid transport protein (FATP). Expression of these transport proteins have 
been shown to be increased in obesity and DM (280,281). Gertow and Colleagues (281) 
observed that increased expression of FATP4 was positively correlated with obesity and 
insulin resistance in monozygotic twins. Based on these studies, it appears that regardless of 
the source of TAG (endogenously produced or dietary), increased storage of TAG in AT 
promotes dyslipidemia and insulin resistance in obese and diabetic individuals.  
 The majority of TAG is from dietary sources; however, de novo lipogenesis (DNL) 
significantly contributes to AT energy reserves. DNL is defined as the synthesis of FA from 
non-lipid sources, primarily glucose. In humans, DNL occurs extensively in the liver (282) 
and is increased substantially in individuals consuming a high carbohydrate (CHO) diet 
(283). FA generated by hepatic DNL are packaged into VLDL for transport to peripheral 
tissues (284). AT is also indicated as a site for DNL in humans. The contribution of DNL in 
AT compared to liver is lower on a per gram of tissue basis, but considering the total amount 
of AT, especially in obese individuals, the overall contribution of FA is similar between the 
two tissues (285). Furthermore, in humans, high a CHO diet appears to mediate little effect 
on DNL in AT (285). Alternatively, the reduction in DNL observed in liver with a high fat 
diet is not seen in AT (286), indicating that DNL in AT is less susceptible to nutrition or 
endocrine regulation. However, the mechanisms regulating DNL in AT and its implication in 
obesity are not fully understood. 
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AT is not only an important site of FA/TAG synthesis and storage but also represents 
a significant site of oxidative FA metabolism (287). Although the total amount of FA 
oxidized in WAT is insubstantial compared to skeletal muscle (288), the large concentration 
of mitochondria found within white adipocytes indicates these cells are involved in oxidation 
of FA (289). Furthermore, several studies (290) elucidated that while the amount of 
oxidation occurring in AT is small, it is inconsistant enough to reduce redistribution of lipid 
to other tissues such as liver. Masseen and colleagues (287,290) suggested that FA in cytosol 
of white adipocytes was cleared through mitochondrial oxidation, thus limiting release of 
FFA into circulation. Moreover, they proposed that with a greater increase in cytosolic FA 
concentration, mitochondrial uncoupling occurs, further reducing FFA released into 
circulation and thus preventing lipotoxicity (290). Mitochondrial uncoupling allows a greater 
amount of FA to be removed through the generation of heat rather than ATP production. In 
obesity an increase influx of FA into the cytosol of adipocytes may exceed the protective 
capacity of FA oxidation and mitochondrial uncoupling, thus resulting in greater amounts of 
FFA released into circulation (287,290). The subsequent increase in plasma FFA contributes 
to ectopic TAG accumulation in non-AT (i.e. pancreas, liver, and skeletal muscle), which 
promotes the development of insulin resistance (291).  
Additional studies examining the oxidative capacity of white adipocytes suggested 
involvement of AMP-activated protein kinase (AMPK) and UCP1 in the regulation of 
adipose-specific FA oxidation (292,293).  Rossmeisl et al. (293) reported that overexpression 
of UCP1 in AT of transgenic mice increased FA oxidation, as well as reduced FA synthesis 
and lipolysis in white adipocytes through an AMPK-mediated mechanism. Moreover, ADN 
was observed to activate AMPK signaling (294), suggesting that adipocytes regulate FA 
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oxidation in a variety of tissues, including adipocytes. Obesity is associated with a reduction 
in ADN and AMPK expression in adipocytes, indicating that downregulation of these genes 
may contribute to the reduced FA oxidation observed in obesity (295).   
Lipolysis, which is the hydrolysis of TAG into FFA and glycerol in adipocytes, is 
catalyzed by hormone sensitive lipase (HSL) (284). Activation of HSL is mediated by 
catecholamines and additional endocrine signals, including adenosine, and prostaglandins 
through interactions with adrenergic receptors (296). Signaling through these receptors leads 
to activation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) which 
in turn activates HSL (284). The cAMP/PKA also mediates phosphorylation of the 
phosphoprotein perilipin, which surrounds lipid droplets and serves as a docking protein for 
HSL (284). The antilipolytic effect of insulin is mediated through increasing intracellular 
phosphodiesterase that subsequently reduces PKA-mediated HSL activation (297). Obesity is 
characterized by high circulating FFA (185,251). This would suggest that obesity is 
associated with greater levels of lipolysis. However, several studies have demonstrated that 
adipocytes were resistant to catecholamine-induced lipolysis (298). Moreover, HSL activity 
has been shown to be dramatically reduced in obese individuals (284). This metabolic 
paradox may be partially explained by an increase in basal lipolysis. The exact mechanisms 
regulating basal lipolysis are not fully elucidated, but may be related to adipocyte size (299). 
Therefore, adipocyte hypertrophy leads to increased basal lipolysis that in turn leads to FFA-
induced insulin resistance in skeletal muscle and liver. 
Obesity-Induced Cytokine Production in Adipose Tissue 
 
 The primary connection between obesity and DM may be the development of AT 
inflammation. Hotamisligil and colleagues (4) originally demonstrated that obesity is 
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associated with increased TNFα release from AT. This group subsequently reported that 
adipose-specific TNFα mRNA expression was negatively correlated with insulin sensitivity 
in obese postmenopausal women (300). The source of this increased TNFα expression in AT 
was initially attributed to adipocytes, but several groups (6,301,302) recently reported that 
the stromal vascular fraction (SVF) of AT released greater levels of TNFα than neighboring 
adipocytes. Cells located in the SVF include preadipocytes, endothelial cells, smooth muscle 
cells, leukocytes, and macrophages. Weisberg and colleagues (7) suggested that adipose 
tissue macrophages (ATM) represented the major source of TNFα. Regardless of the source, 
TNFα contributes to the activation of several proinflammatory intermediates, such as NFκB 
and MAPK (including ERK1/2, p38 MAPK and JNK). Activation of these pathways in 
obesity mediates insulin resistance. Moreover, increased expression of TNFα in AT precedes 
the development of systemic insulin resistance, indicating that obesity-induced TNFα 
expression in AT is a mediator of the reduced insulin sensitivity observed in obesity.  
The regulation of TNFα-induced insulin resistance in obesity may be mediated by direct 
or indirect mechanisms. Several groups (78,94,95,98) have demonstrated that TNFα mediates 
insulin resistance in skeletal muscle. Plomgaard et al. (95) reported that infusion of TNFα in 
healthy humans induced insulin resistance in skeletal muscle through disruption of insulin 
signaling. Specifically, TNFα inhibited tyrosine phosphorylation of IR and IRS, as well as 
increases serine (inhibitory) phosphorylation of IRS and Akt/PKB, leading to reduced 
insulin-stimulated glucose uptake (94,95,98). TNFα impairment of insulin signaling involves 
activation of proinflammatory intermediates, such as NFκB, ERK1/2, JNK, and PKC. 
Furthermore, obesity-induced activation of these pathways and subsequent serine 
phosphorylation of IR were attenuated in TNFα or TNFα receptor-deficient mice (303,304). 
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These data indicate the importance of this cytokine in obesity-induced insulin resistance. 
However, Ofei and colleagues (305) demonstrated that TNFα-neutralizing antibody failed to 
improve insulin sensitivity in obese individuals diagnosed with DM. This study suggested 
that in vivo circulating TNFα may not be sufficient to induce obesity-induced insulin 
resistance.  
One potential explanation is that TNFα released from AT functions in an autocrine or 
paracrine manner to regulate adipocyte metabolism. It is established that TNFα causes 
insulin resistance in adipocytes (306). This cytokine can block insulin-stimulated IR, IRS, 
and GLUT4 activation (307,308). Moreover, TNFα-induced insulin resistance in adipocytes 
involves signaling through JNK (100) and NFκB (307). This inflammatory signaling 
contributed to accumulation of ROS (309), which can further exacerbate insulin resistance. 
TNFα signaling also mediates several physiological changes in adipocyte metabolism, 
including reduced lipogenesis and increased lipolysis. The reduction in lipogenesis involves 
impaired insulin-stimulated glucose and FA uptake. Mechanisms mediating TNFα-induced 
inhibition of FA uptake are not well understood, but may involve downregulation of FATP, 
as well as decreased LPL activity (310,311). The induction of lipolysis and release of FFA 
contributes to the development of systemic insulin resistance, which is likely mediated 
through an inflammatory response initiated within skeletal muscle. Mechanistically, TNFα 
stimulates lipolysis through activation of kinases such as JNK and ERK1/2, which decreased 
the expression of antilipolytic genes (312). TNFα-induced lipolysis may also be exacerbated 
by inhibition of adipogenesis. Several groups (313,314) have reported that TNFα reduced 
PPARγ expression and activity. Therefore, TNFα-induced inflammation and insulin 
resistance in AT mediates systemic insulin resistance through release of FFA.   
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  IL-6 is another important adipokine involved in obesity-induced insulin resistance. 
AT secretion represents 10 to 35% of circulating IL-6 (315). Adipocytes themselves express 
and secrete IL-6 (22,84); however, their overall contribution to sera IL-6 concentration may 
be limited as the SVF contributes a significant proportion of  IL-6 released from AT (316). 
Adipocyte hypertrophy is coupled with increased IL-6 production (317).  Moreover, 
Mohamed-Ali, et al. (318) reported that in obesity, adipocytes may contribute up to 30% of 
total circulating IL-6. There are two major signaling pathways activated by IL-6: the Janus 
kinase/signal transducer and activator of transcription (JAK/STAT) pathway and the 
MAPK cascade (319). Activation of these inflammatory pathways contributes to obesity-
induced insulin resistance. 
 Like TNFα, the regulation of IL-6-induced insulin resistance in obesity may be due to 
direct and/or indirect effects on peripheral tissues, including skeletal muscle and liver. 
Several studies have suggested that IL-6 is responsible for hepatic insulin resistance 
(81,83,237). Klover and colleagues (237) demonstrated that reductions in plasma IL-6, 
mediated by neutralizing antibody specific for IL-6, were associated with improved hepatic 
insulin sensitivity. These effects can be attributed to improvements in insulin signaling, 
which include increased activation of IR, IRS, PI3K, and Akt/PKB (81,237). Moreover, IL-6 
has been shown to induce STAT3 and suppressors of cytokine signaling (SOCS) (81,83,237). 
Blocking these inflammatory intermediates led to improvements in hepatic insulin sensitivity 
(237). Interestingly, the effect of circulating IL-6 on insulin sensitivity in skeletal muscle is 
less clear. In fact, minutes within starting exercise, the intracellular concentration of IL-6 
increased 100-fold in muscle cells (237). Febbraio and colleagues (320) reported that this 
elevation in IL-6 during exercise was associated with an increase in whole body glucose 
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uptake. Furthermore, IL-6 deficient mice show a reduced capacity for aerobic exercise (321). 
Therefore, these data indicate that in terms of skeletal muscle physiology, IL-6 has an 
important function in energy metabolism during exercise.  
 The paradoxical relationship between circulating IL-6 and systemic insulin resistance 
may be partially explained by the autocrine and paracrine effects of IL-6 on adipocytes. 
Several groups (80,84) reported that IL-6 blunted insulin-stimulated IR, IRS-1, Akt/PKB, 
and GLUT4 activation in adipocytes. Accompanying the development of insulin resistance is 
a reduction in adipose-specific LPL activity (322). Hence, the lipogenic activity of 
adipocytes is dramatically impaired by IL-6 through blocking the entry of substrates (glucose 
and FFA) necessary for TAG synthesis. Along with the reduction in lipogenesis is a 
corresponding increase in lipolysis (323,324). Peterson and colleagues (323) observed that 
acute infusion of IL-6 stimulated lipolysis in elderly subjects. The overall implication of IL-6 
in adipocyte metabolism is a reduced capacity for lipid storage and increased flux of FFA 
into the circulation. Thus, increased adipocyte hypertrophy stimulates IL-6 production and 
release from adipocytes, which in turn exacerbates lipolysis and FFA-induced insulin 
resistance in skeletal muscle. This effect is further supported by a recent study that observed 
conditioned medium from mature lipolytic adipocytes that stimulate inflammation and 
insulin resistance in skeletal muscle (325). 
Obesity-Induced Macrophage Accumulation in Adipose Tissue 
 
Obesity is associated with increased cytokine expression and proinflammatory 
signaling in AT. Corresponding with this inflammation of AT is an increase in macrophage 
infiltration (3,6,7). Weisberg and colleagues (7) reported that adipocyte size was positively 
correlated with expression of the macrophage marker F4/80 in AT of obese mice. In humans, 
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the macrophage marker CD68 was correlated with BMI, as well as adipocyte size (7). The 
majority (85%) of adipose-specific cells are thought to be derived from bone marrow (7). 
However, the ability of preadipocytes to exhibit a macrophage-like phenotype, which 
includes expression of macrophage-specific cell surface markers (i.e. F4/80 and Mac-1) and 
phagocytic activity, also have implications in AT inflammation (326). In terms of ATM, it is 
known that these cells originate from progenitor cells in bone marrow. Furthermore, there are 
two major subpopulations of ATM, which includes a short-lived subset actively recruited to 
inflamed AT and a subset that is constitutively localized to AT (327). Lumeng and 
colleagues (328) also suggested that resident ATM undergo a phenotypic change in response 
to obesity that results in an enhanced proinflammatory response.  Macrophage infiltration 
into AT (diapedesis) involves several steps that include: activation of capillary endothelium, 
increased expression of adhesion molecules and attachment of blood monocytes, 
transmigration of monocytes through endothelial cells, and differentiation of monocytes to 
ATM (329). Recruitment of macrophages is commonly observed in ischemic and hypoxic 
tissues (330). Within AT, macrophages localize primarily to sites of necrotic-like adipocyte 
cell death and aggregate in crown-like structures (CLS) around individual adipocytes (331). 
Cinti, et al. (331) demonstrated in HSL knockout mice that there was excessive adipocyte 
hypertrophy associated with necrosis and subsequent macrophage accumulation. Based on 
these data, it is evident that one of the ATM functions is to clear necrotic adipocytes.  
Another proposed function of macrophages is the stimulation of AT remodeling as 
observed in obesity. The expansion of AT is associated with increased adipogenesis coupled 
with angiogenesis (332,333). Macrophages have been shown to mediate angiogenesis during 
tumor growth (334) and inflammation (335). More recently, Pang and colleagues (336) 
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reported that macrophages induced angiogenesis in AT of obese mice through increased 
expression of platelet-derived growth factor (PDGF). Hence, ATM may regulate 
neovascularlization in expanding AT in response to reduced vascular density. Alternatively, 
macrophages were observed to impair adipogenesis in humans through inhibition of 
adipocyte differentiation (337-339). Kim and colleagues (339) also reported that macrophage 
inflammatory protein-related protein-2 (MRP-2) inhibited adipocyte differentiation but 
promoted preadipocyte migration. The ability of infiltrating macrophages to regulate 
adipocyte differentiation may in fact exacerbate obesity-induced inflammation and insulin 
resistance through several distinct mechanisms. Specifically, impairment of adipocyte 
differentiation contributed to reduced lipid storage capacity and subsequently increased 
circulating FFA (339), leading to insulin resistance in adipocytes or in peripheral tissues (i.e., 
skeletal muscle and liver). Furthermore, ATM may cause preadipocytes to exhibit a 
proinflammatory phenotype characterized by increased local and systemic cytokine 
concentrations (15,326). Regardless of the exact mechanism, the involvement of ATM in 
obesity-induced insulin resistance is apparent, as obese mice deficient in macrophage-
specific inflammatory signaling were protected from obesity-induced insulin resistance 
(340). 
The regulation of macrophage infiltration into AT is not fully elucidated but likely 
involves multiple mechanisms including the release of proinflammatory chemokines from 
hypertrophic adipocytes (7). Numerous chemoattractant proteins, such as MCP-1 and colony-
stimulating factor (CSF), were suggested mediators of macrophage infiltration in AT (6,7). 
Leptin is also involved in endothelial cell activation and monocyte transmigration (329). 
However, leptin deficient ob/ob mice still exhibited macrophage accumulation in AT (6), 
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indicating involvement of additional chemokines. One potential candidate is MCP-1, which 
is thought to be one of the most potent chemokines regulating macrophage infiltration. 
Adipocytes, endothelial cells, and macrophages have all been observed to contribute to the 
release of this chemokine from AT (69,341,342). Christiansen et al. (343) reported that 
MCP-1 mRNA expression in AT was correlated with circulating MCP-1 concentration, 
indicating that AT is the primary source of the chemokine in obesity and was associated with 
insulin resistance. Westerbacka and colleagues (344) reported that obese and insulin resistant 
women exhibited a more pronounced increase in adipose-specific MCP-1 gene expression 
compared to lean subjects. Collectively, these studies suggest that adipocytes release 
chemokines in response to hypertrophy. This in turn stimulates recruitment of macrophages 
and increased production of cytokines/chemokines from adipocytes and macrophages, as 
well as increased lipolysis, thus promoting systemic inflammation and insulin resistance. 
Obesity-Induced Inflammation and Insulin Resistance: Toll-like Receptor 2 and 4 
 
Overview of Toll-like Receptors 
 
 Toll-like receptors (Tlrs) are germline-encoded receptors expressed on a variety of 
innate immune cells. In mammals, there are currently 13 identified isoforms of Tlrs (345). 
Each Tlr recognizes distinct structural motifs primarily expressed on foreign pathogens such 
as bacteria, viruses, fungi, and protozoa. These pathogen-associated molecular patterns 
(PAMPs) range from specific lipids to nucleic acid sequences. For instance, Tlr4 recognizes 
lipid based structures, such as LPS, whereas Tlr3 recognizes double stranded viral DNA 
(345,346). The cellular location of Tlrs is an important factor in determining their respective 
ligands. Tlrs located on the plasma membrane (i.e. Tlr1, 2, 4, 5, 6, 10, and 11) commonly 
recognize lipid or protein based PAMPs (347). Alternatively, intracellular based Tlrs (i.e. 
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Tlr3, 7, 8, and 9) most commonly recognize bacterial and viral nucleic acids (347). The wide 
distribution in pathogen recognition of Tlrs, as well as their extensive in vivo expression 
indicates their importance in host defense. Tlrs are expressed on immune cells involved in 
innate and adaptive immunity, including macrophages, neutrophils, dendritic cells, and T and 
B lymphocytes (346). More recently, expression of these innate immune receptors were 
identified in cells not traditionally characterized as immune cells, such as intestinal epithelial 
cells (348), myotubes (349-351), and adipocytes (20).   
 The activation of Tlrs through interactions with their respective ligand or PAMP 
leads to an inflammatory response mediated by a common signaling pathway (345,346). The 
initial event following ligand binding is the recruitment of adaptor proteins to the 
intracellular domain of Tlrs. These adaptor proteins, include MyD88, TIR domain-containing 
adaptor protein (TIRAP), Trif, and TRAM (352). MyD88 is the most prominent adaptor 
protein involved in the majority of Tlr signaling. In fact, only Tlr3 and Tlr4 are capable of 
signaling independently of MyD88 (352). The more prominent MyD88 dependent pathway 
involves several additional proteins including IL-1R-associated kinase (IRAK) and TNF 
receptor-associated factor 6 (TRAF6). Phosphorylation of IRAK activates TRAF6, which 
subsequently activates IKK and MAPK signaling pathways (347,352). Several groups 
(353,354) suggested that TRAF6 interacts with membrane-associated proteins, such as 
transforming growth factor-ß-activated kinase 1(TAK1) (transforming growth factor-(ß-
activated kinase 1) and transforming growth factor-(ß-activated protein kinase-1-binding 
protein 1 (TAB1) leading to activation of IKK and MAPK pathways. However, the exact 
mechanisms are yet to be fully elucidated. 
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Activation of IKK mediates phosphorylation of IκB, marking the inhibitor protein for 
degradation.  This is followed by nuclear translocation of NFκB, which induces expression 
of proinflammatory genes (355). There is evidence that MyD88-independent pathways may 
also induce NFκB activation through a delayed induction mediated through Tlr4 (356,357). 
Alternatively, activation of MAPK requires MyD88 for an inflammatory response to occur 
(352). Activation of the MAPK family, including JNK, ERK1/2, and p38, results in nuclear 
translocation of the transcription factor, AP-1 (358,359).  Both NFκB and AP-1 are required 
for cytokine production, but it is unknown how activation of these transcription factors and 
the corresponding proinflammatory gene expression are affected by signaling through 
distinct Tlrs. 
Tlr4- and Tlr2-Induced Inflammation and Insulin Resistance 
 
 Tlr4. LPS is a major component of the gram-negative bacterial envelope and a 
known inducer of inflammation in vivo (360). The proinflammatory component of LPS, 
endotoxin (or lipid A), is composed of FA and phosphate groups attached to a central 
glucosamine dimer (360). A specific serum binding protein transports endotoxin to cells 
expressing its corresponding receptor, which was recently identified as Tlr4 (361). The Tlr4 
complex consists of the Tlr4 receptor itself and two co-receptors, MD-2 and CD14 (362). 
The MD-2 co-receptor is essential to Tlr4 function (363), whereas CD14 is a high affinity 
GPI-linked protein necessary for LPS binding (364). Following binding of LPS to CD14, 
Tlr4 is close enough to recognize endotoxin and initiate signal transduction through MyD88-
dependent and independent pathways (360). 
 Several studies (365-370) have examined the impact of SNP in the Tlr4 gene on the 
development of CVD and DM. The findings of these studies are mixed but indicate that 
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certain polymorphisms exhibit protective effects. For instance, the Asp299Gly SNP was 
associated with changes in extracellular domain of Tlr4 causing reduced sensitivity to LPS 
(371).  Data from the Bruneck Study (365) determined that 53 of 810 subjects were 
heterozygous for Asp299Gly SNP. Furthermore, carriers of this allele exhibited lower 
proinflammatory cytokines, ACP, and adhesion molecules, which was associated with lower 
atherosclerotic risk (365). Edfeldt and colleagues (370) also reported that this SNP was 
associated with reduced incidence of myocardial infarction in a Swedish population. Kolek et 
al. (369) reported a reduction in CVD and DM risk with individuals exhibiting the 
Asp299Gly SNP. More specifically, presence of the SNP has been associated with lower 
circulating CRP, with a simultaneous reduction in CVD and DM prevalence (369). 
Alternatively, several studies have indicated that polymorphisms in Tlr4 have little impact on 
progression of chronic disease in humans (366,367). The disparities among these studies are 
difficult to explain and may be attributed to different populations. 
 Despite the conflicting genetic reports on Tlr4 polymorphisms in the development of 
CVD and DM, there is substantial evidence that the innate immune receptor is a major 
mediator of obesity-induced insulin resistance. Studies using the Tlr4 ligand, LPS, clearly 
showed the importance of the receptor in the development of insulin resistance in several cell 
types, including myotubes (372,373), hepatocytes (374), and adipocytes (23). Frost and 
colleagues (372) suggested that LPS-induced insulin resistance in C2C12 myotubes was 
mediated through Tlr4-induced activation of NFκB and JNK/AP-1,  leading to production of 
TNFα and IL-6, respectively. Moreover, these effects were attenuated in skeletal muscle of 
Tlr4 deficient mice (372). Inflammation was also attributed to the LPS/Tlr4-mediated insulin 
  47
resistance in hepatocytes and adipocytes (23,374). Song et al. (23) observed that LPS 
stimulated TNFα and IL-6 expression, which in turn resulted in impaired insulin signaling.  
There is also evidence that obesity is associated with increased circulating LPS, a 
major in vivo agonist of Tlr4, and that this endoxemia is a primary mediator of insulin 
resistance (16,375). Cani and colleagues (375) demonstrated that plasma LPS was increased 
in obese mice. In humans, serum endotoxin levels are reported to be over 75% higher in 
diabetic subjects compared to non-DM controls (16).  Furthermore, increased circulating 
LPS concentration was associated with insulin resistance in obesity, implicating a role of 
Tlr4 in obesity-induced inflammation. For instance, Tlr4 deficient mice were protected from 
obesity-induced insulin resistance (24,376,377). More specifically, Suganami and colleagues 
(24) observed that C3H/HeJ mice, with a missense mutation in the cytoplasmic domain of 
Tlr4, exhibited reduced TNFα expression in AT and improved insulin sensitivity following 
16 weeks of a high fat diet (HFD) (24). These findings are supported by two recent studies 
(376,377). However, the impact of aberrant Tlr4 signaling on adiposity remains unclear. 
Tsukumo et al. (377) reported a reduction in epidydimal fat pad weight due to increased 
oxygen consumption and reduced respiratory exchange ratio, although the exact mechanisms 
are unknown. Alternatively, Poggi and colleagues (376) observed an increase in adiposity in 
HFD fed C3H/HeJ mice. The disparity between these studies may be due to distinct 
differences in diet composition, but this requires further investigation. Additional 
investigations demonstrated that Tlr4 may also be involved in the development of 
atherosclerosis (378-380). More specifically, Tlr4 is expressed in lipid-rich macrophage-
infiltrated atherosclerotic lesions of mice and humans (380). Furthermore, Kim and 
colleagues (378) observed that Tlr4 knockout mice were protected from HFD-induced 
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vascular inflammation as determined by reduced NFκB activation and NO production. 
Overall, these studies indicate that Tlr4 may be a potential mediator of obesity-induced 
insulin resistance and related co-morbidities, including DM and CVD. 
Tlr2. Of the various innate immune receptors, Tlr2 recognizes the most diverse 
number of microorganisms. PAMPs commonly recognized by Tlr2 include glycolipids (i.e. 
lipoteichoic acid and peptidoglycan), polysaccharides (i.e. zymosan), and whole bacteria 
(381,382). LPS was originally characterized as a Tlr2 agonist (383), but it was later 
determined that this effect was mediated by contaminating lipoproteins (384). However, two 
studies (385,386) reported that Tlr2 recognized atypical forms of LPS from Leptospira 
interrogans and Porphyromonas gingivalis. The atypical forms of LPS differ in structure and 
function than the type recognized by Tlr4 by their different number of acyl groups in the 
lipid A component (387). Regardless of the exact agonist, Tlr2 activation requires 
dimerization with Tlr1 or Tlr6 (388,389). The specific heterodimer formed in the Tlr2 
complex appears to be dependent on the size and number of fatty acyl chains. However, post-
receptor signaling appears to be the same for both dimers.  
There are currently 16 polymorphisms identified in the Tlr2 gene. Of these, half are 
non-synonymous mutations leading to amino acid exchanges and the remaining half are 
synonymous polymorphisms (390). There is limited research investigating the relationship 
between Tlr2 polymorphisms and obesity-related co-morbidities. However, two studies 
(390,391) demonstrated SNPs in the Tlr2 gene that were associated with reduced cytokine 
production. More specifically, Merx and Colleagues (390) reported a novel SNP in Tlr2 
(arginine codon at 447 to stop codon) associated with reduced IL-6 and TNFα production in 
heterozygote Arg447 stop individuals. Additional genetic analyses have observed that 
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various SNP in Tlr2 were protective against several inflammatory conditions, including Type 
1 DM (392) and coronary endothelial dysfunction (393).  
Despite the limited genetic analysis, there is evidence to suggest involvement of Tlr2 
in obesity-induced inflammation and insulin resistance. Creely, et a. (16) reported that 
expression of Tlr2 was increased in AT of obese diabetic individuals, whereas Tlr4 levels 
were unchanged. Furthermore, expression of this innate immune receptor was associated 
with increased inflammatory signaling, including activation of NFκB and induction of 
proinflammatory cytokine expression (16). Murakami and colleagues (394) utilized flow 
cytometry to analyze isolated adipocytes from obese mice and observed that these cells co-
express Tlr2 and TNFα. Moreover, expression of these proteins was associated with insulin 
resistance (394). The exact mechanisms involved in regulation of Tlr2 expression are unclear 
but may be related to elevated endotoxin levels (16,20). As mentioned previously, certain 
forms of LPS may interact directly with Tlr2 (387). However, recent evidence indicates that 
LPS may also indirectly regulate Tlr2 through a Tlr4-specific pathway (20). These studies 
indicated a potential role of Tlr2 in the development of obesity-induced inflammation and 
insulin resistance. 
Fatty Acid-Induced Tlr2 and Tlr4 Signaling 
 
 Investigations into the structure of endotoxin, the bioactive component of LPS, 
revealed the presence of acyl-linked SFAs (395). Furthermore, these acylated FAs were 
subject to hydrolysis, which subsequently reduced the endotoxic properties (396,397). 
Kitchens and colleagues (397) reported that deacylated LPS (dLPS) antagonized LPS-
induced NFκB activation and TNFα expression in a human monocyte cell line. Moreover, 
deacylation of bacterial lipopeptides resulted in a reduction of Tlr2 to initiate a 
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proinflammatory response in human monocytes (398). These data suggest that FAs, 
specifically SFAs, act as endogenous ligands for Tlrs. Lee et al. (399) originally reported that 
SFA stimulated NFκB activation and cyclooxygenase-2 (COX2) activity through a Tlr4-
dependent mechanism. Additional studies (25,400) confirmed the involvement of SFA in 
Tlr4 signaling that included activation of MyD88, IRAK-1, TRAF6, and PI3K-Akt pathways. 
However, Lee and colleagues (26) demonstrated that SFA increased COX2 promoter activity 
in bone marrow-derived macrophages (BMDM) independent of Tlr4. Moreover, this 
inflammatory response stimulated dimerization of Tlr2 with its co-receptors Tlr1 or Tlr6 
(26). More recently, Nguyen et al. (401) demonstrated that FFAs mediated IL-6, TNFα, and 
MCP-1 gene expression in macrophages through Tlr2 and Tlr4 activation of JNK. Therefore, 
these data demonstrate the importance of both innate immune receptors in FA-induced 
inflammation. 
 Obesity is associated with an increase in circulating FFA (185,251). Subsequently 
this promotes Tlr signaling in insulin sensitive tissues, such as skeletal muscle and AT. For 
instance, Reyna and colleagues (402) showed FFA concentration was associated with an 
increase in Tlr4 gene and protein expression. Moreover, there was a strong correlation 
between insulin resistance and Tlr4 expression in obese and diabetic subjects (402). 
Alternatively, Senn (403) demonstrated that palmitate stimulated Tlr2 signaling in C2C12 
myotubes, leading to activation of the proinflammatory mediators, JNK and NFκB, as well as 
reduced insulin-stimulated glucose uptake. Additionally, there is evidence that SFAs mediate 
inflammation and insulin resistance in AT through Tlr-dependent mechanisms. Shi et al. (25) 
observed that FFA-induced TNFα and IL-6 expression in adipocytes was attenuated in Tlr4 
knockout mice. Furthermore, these mice were protected from FFA-induced NFκB activation 
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and impaired insulin signaling in AT (25). Additional studies (376-378) confirmed that Tlr4 
deficient mice exhibited greater insulin sensitivity than their wild type counterparts, and that 
this effect may be a consequence of reduced inflammatory signaling in AT.  
Macrophage infiltration is a primary contributor to AT inflammation. Furthermore, 
several studies (24,401,404) suggested that SFA signaling through Tlr4 is a potential 
mechanism involved in this process. Suganami and colleagues (404) utilized a co-culture 
system of adipocytes and macrophages to determine that FFA released from hypertrophied 
adipocytes serve as ligands for Tlr4 expressed on macrophages, as well as adipocytes 
themselves. Moreover, the Tlr4-NFκB pathway is critical in palmitate-induced TNFα 
expression in macrophages, and subsequent FFA release from adipocytes. These studies 
indicate that FFA released from hypertrophied adipocytes act in a paracrine and autocrine 
manner to stimulate Tlr receptors on macrophages and adipocytes located in AT and 
subsequently cause local inflammation and insulin resistance. Moreover, FFAs released from 
AT can then interact with Tlrs expressed in peripheral tissues, including skeletal muscle and 
liver, causing inflammation and insulin resistance in these tissues.     
As discussed previously, certain MUFA and PUFA have been shown to exert anti-
inflammatory properties both in vitro and in vivo (225-229). One potential explanation for 
these effects may be through antagonism of Tlr2 and Tlr4 signaling. Several investigations 
(26,399,400) reported that the PUFAs, DHA and EPA, antagonized SFA-induced Tlr 
signaling in RAW 264.7 macrophages. Moreover, Lee and colleagues (405) demonstrated 
that monocytes isolated from subjects fed 9 to 15 g fish oil (rich in omega-3 FA) per day for 
8 weeks exhibited a reduction in Tlr2 and Tlr4 agonist-mediated COX2 expression and 
NFκB activation. Overall, these studies indicate that SFAs act as endogenous ligands for Tlr2 
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and Tlr4, whereas PUFAs antagonize Tlr signaling, likely through a direct interaction with 
these receptors.  
Summary 
 
 The prevalence of obesity continues to rise dramatically in the U.S. and worldwide. 
Corresponding to this rise is an increase in obesity-related co-morbidities, such as DM and 
CVD. The underlying mechanism linking obesity to these diseases is the development of 
insulin resistance, which is further attributed to a state of chronic low-grade inflammation 
characterized by elevation in proinflammatory cytokines. Furthermore, FFA levels are 
increased in obesity and induce insulin resistance through a variety of mechanisms including 
inflammation and oxidative stress. However, obesity-induced changes in AT appear to 
precede the development of systemic inflammation and insulin resistance. Adipocyte 
hypertrophy represents the initial event contributing to AT inflammation. In response to 
increased lipid accumulation, adipocytes secrete greater amounts of FFA and 
proinflammatory cytokines into the circulation. These inflammatory mediators can then act 
in an autocrine or paracrine manner to activate surrounding cells, including macrophages, 
endothelial cells, and neighboring adipocytes. These events promote recruitment of immune 
cells into AT and further amplify the release of inflammatory mediators from AT, thus 
contributing to inflammation in other insulin-sensitive tissues (i.e., liver and skeletal muscle), 
resulting in subsequent insulin resistance. The ability of FFA, more specifically SFA, to 
induce inflammation and insulin resistance may be dependent on the presence of specific 
innate immune receptors. Tlrs recognize specific PAMPs on invading pathogens, initiating a 
proinflammatory response to aid in host defense. More recently, Tlr2 and Tlr4 were observed 
to mediate SFA-induced inflammation in AT and other insulin-sensitive tissues. Preliminary 
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investigations on these receptors demonstrate their potential involvement in DM and CVD. 
Furthermore, elucidating the role of Tlr2 and Tlr4 in AT inflammation will provide greater 
insight into the development of obesity-related co-morbidities and help identify novel 
nutritional and pharmaceutical therapies. 
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CHAPTER 3.  TLR4 DEFICIENCY SELECTIVELY PROTECTS AGAINST 
OBESITY INDUCED BY DIETS HIGH IN SATURATED FAT 
(Published in Obesity) 
 
Abstract 
 
Toll-like receptor-4 (Tlr4), a key pattern recognition receptor involved in innate 
immune response, is activated by saturated fatty acids (SFAs). To investigate the 
involvement of this receptor in obesity caused by consumption of diets high in fat, we 
utilized male Tlr4-deficient 10ScN mice and 10J controls. Mice were fed either low fat (low-
fat control (LFC)), high unsaturated fat (high-fat control (HFC)), or high saturated fat + 
palmitate (HFP) diets ad libitum for 16 weeks. Relative to the LFC diet, the HFC diet 
resulted in greater epididymal fat pad weights and adipocyte hypertrophy in both Tlr4-
deficient and normal mice. However, the 10ScN mice were completely protected against the 
obesigenic effects of the HFP diet. Moreover, macrophage infiltration and monocyte 
chemotactic protein-1 transcript abundance were lower in adipose tissue of 10ScN mice fed 
the HFP diet, and the hyperinsulinemic response was negated. Tlr4-deficient mice also had 
markedly lower circulating concentration of MCP-1 and much less nuclear factor-κB protein 
in nuclear extracts prepared from adipose tissue, irrespective of diet. In contrast, Tlr4 
deficiency did not attenuate the induction of tumor necrosis factor-α or interleukin-6 
expression in adipose tissue. These data indicate that Tlr4 deficiency selectively protects 
against the obesigenic effects of SFA by selectively altenatings obesity-related inflammatory 
responses in adipose tissue. 
Introduction 
 
Obesity is associated with chronic low-grade inflammation (1-4) that is characterized by 
increased circulating concentrations of proinflammatory cytokines (5-7) and acute phase 
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proteins (8,9), and decreased concentrations of the anti-inflammatory protein adiponectin 
(10).  Although the mechanisms underlying the onset and progression of this inflammatory 
state remain somewhat ambiguous, two recent findings have strongly implicated the adipose 
tissue itself as a major contributor.  First, genetic and diet-induced obesity models have not 
only shown increased expression of proinflammatory cytokines in the adipose tissue 
(1,3,11,12), but also a marked adipose-specific infiltration of macrophages that show gene 
expression profiles consistent with inflammation (13-15).  Secondly, the adipocyte itself is 
capable of mounting a classical innate immune response initiated by ligand activation of 
Toll-like receptor-4 (Tlr4), followed by activation of nuclear factor-κB (NFĸB), increases in 
proinflammatory gene expression and the release of these cytokines from cultured adipocytes 
(16-18).  Furthermore, both Tlr2 and Tlr4 expression are increased in adipose tissue in 
association with obesity and Type 2 diabetes mellitus (DM) (19). 
It is clear from multiple obesity models that adipocytes and macrophages, localized in 
adipose tissue, produce proinflammatory mediators, the mechanistic links among adipocyte 
hypertrophy, dietary fat, inflammation, and macrophage recruitment and activation have not 
been delineated.  However, direct regulation of Tlr4 by certain saturated fatty acids (SFA) is 
a likely component of this process because palmitate and other SFA act directly to stimulate 
proinflammatory cytokine expression and NFĸB activation in cultured adipocytes and 
macrophages (20,21). Furthermore, Suganami and colleagues (21) recently determined that 
free fatty acids (FFA) released from hypertrophic adipocytes can signal macrophages through 
Tlr4 and stimulate release of tumor necrosis factorα (TNFα). Additional studies by other 
groups (20,22-24) have shown that Tlr4 deficient mice are less susceptible to fat-induced 
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inflammation and insulin resistance, and that C3H/HeJ mice are protected against 
hyperglycemia and inflammation in adipose tissue when Tlr4 signaling is blunted (22). 
 Although the link between a functional Tlr4 receptor and obesity-induced 
inflammation in adipose tissue seems quite clear, whether this receptor contributes to the 
onset and progression of obesity is controversial.  Elegant in vivo studies with a Tlr4 
knockout mouse model have shown blunted inflammation, yet a greater adiposity in females 
(23).  In contrast, Tsukomo et al. (25) recently reported evidence that a loss of function 
mutation in Tlr4 protects against high fat, diet-induced obesity.  Albeit, there is currently a 
paucity of data that address the possibility that dietary SFA vs. unsaturated fatty acids (UFA) 
influence the ability of Tlr4 to promote adipose accretion.  Consequently, we used the 10ScN 
mouse strain, which has a 74 kb deletion from chromosome 4 that precludes expression and 
production of Tlr4, to test the hypothesis that Tlr4 specifically mediates obesity and 
inflammation associated with a diet high in saturated fat.       
Materials and Methods 
 
Animals and animal care. Male Tlr4 deficient C57BL/10ScN mice (Cat No. 003752) 
derived from the C57BL/10 subline and corresponding control male C57BL/10J mice (Cat 
No. 000665), were obtained from Jackson Laboratories (Bar Harbor, ME) at 6-8 weeks of 
age. Subsequently, lack of Tlr4 mRNA was confirmed with real time PCR. Animals were 
housed individually in stainless steel wire-mesh cages at 21° C in a room with an 
automatically controlled 12-hour light:dark cycle. Mice were acclimated to the environment 
and provided unlimited access to food and water. Animals from each genotype were then 
randomly assigned to one of three experimental diets (n = 25/genotype/diet): 1) low fat 
control (LFC), high fat control (HFC), or high fat palmitate (HFP) for 16 weeks. Both high 
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fat diets were semi-purified, powdered diets based on American Institute of Nutrition 
recommendations (26) that were modified to induce obesity by providing 60% of calories 
from lipid (Table 1). The high fat diets were identical except the source of fat used was either 
soybean oil in the HFC (Harlan Teklad) or a mixture of lard (Harlan Teklad) and purified 
palmitate (Nu-Check Prep, Inc.) in the HFP. The LFC diet contained 12% of calories from 
lipid. Food intake was measured daily and used to calculate total energy intake. Mice were 
fasted overnight (6-8 h) and euthanized by CO2 asphyxiation for all blood and tissue 
collections. Blood was collected by heart puncture, placed on ice, and serum was collected 
by centrifugation and frozen at -80oC until analyzed. Animals were weighed and abdominal 
fat pads and liver were removed and weighed. All extracted tissues were immediately frozen 
in liquid nitrogen and stored at -80°C prior to RNA extraction and immuno-histochemical 
analysis. All experimental protocols for animal care and use were approved by the 
Institutional Animal Care and Use Committee at Iowa State University, Ames, IA, USA.  
Analysis of Metabolic Parameters. Serum concentration of glucose (Biovision) and 
insulin (Linco) were measured using commercial assay kits. Leptin, monocyte chemotactic 
protein-1 (MCP-1), adiponectin (ADN), and interleukin-6 (IL-6) serum concentrations were 
measured using ELISA kits (R&D Systems). Serum FFA was measured with NEFA-C 
(Wako Pure Chemical Industries, Inc.) kit. 
Quantitative real-time PCR. Total RNA was extracted from frozen adipose tissue  
using a commercially available acid-phenol reagent (TRIzol, Invitrogen Corp.). Potential 
DNase contamination was removed with DNase-freeTM (Ambion, Inc.). First-strand cDNA 
was synthesized using SuperScript® III First-Strand Synthesis System for RT-PCR 
(Invitrogen Corp.). Primer sequences for mouse sense and anti-sense primers are listed in 
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Table 2. Thermal cycling conditions for PCR reactions were 95°C for 3 min followed by 40 
cycles of 95°C for 15 s, 60°C for 30 s, and 72°C for 30 s. Polymerase reaction products 
amplified by these primers were cloned into pGEMT vector (Promega) and sequenced for 
verification. Real-time reactions were carried out on an iCycler real time machine (BioRad) 
using the IQTM SYBR Green Supermix kit (BioRad). The abundance of each gene product 
was calculated by regressing against the standard curve generated in the same reaction with 
their respective plasmid. All genes of interest were normalized to beta actin and expressed as 
log starting quantity. 
Immunohistochemistry. Frozen adipose tissue was fixed overnight at room 
temperature in 10% zinc-formalin solution and embedded in paraffin. Five micron sections 
were cut at 50 µm intervals and mounted on glass slides, deparaffinized in xylene, and 
stained for expression of F4/80 with monoclonal antibody (Serotec) as previously described 
(14). For each mouse, four different fields were selected and adipocyte area was determined 
using AxioVision v4.5.0.0 (Carl Zeiss, Germany). F4/80-positive macrophages were then 
counted at 40X magnification and divided by total cell number to obtain percent F4/80-
positive cells.  
Tissue and plasma fatty acid profile. Lipids from adipose and serum samples were 
extracted by the method of Lepage and Roy (27) with minor modifications. Briefly, 0.5 g of 
tissue was homogenized in 2.5 mL 4:1 methanol:hexane and 200 µL of 3.7 mmol 
heptadecanoic acid/L methanol was added to each sample as an internal standard. Fatty acid 
methyl esters were analyzed by gas chromatography on a Hewlett-Packard model 6890 
(Hewlett-Packard, Palo Alto, CA) fitted with an Omegawax 320 (30 m x 0.32 mm ID, 0.25 
µm) capillary column (Sigma-Aldrich, St Louis, MO USA). Hydrogen was the carrier gas. 
  91
The temperature program ranged from 80°C to 250°C with a temperature rise of 5°C/min. 
The injector and detector temperatures were 250°C and 1 µL of sample was injected and run 
splitless. Fatty acids were identified by their retention times on the column with respect to 
appropriate standards. 
EMSA and Activated NFĸB p65 ELISA. Adipose tissue nuclear extracts and mobility 
shift assay were prepared and validated as previously described (16). The consensus NF-B 
oligonucleotides (Santa Cruz) were end-labeled with [-32P]ATP (PerkinElmer) using T4 
polynucleotide kinase (Santa Cruz). Binding of nuclear proteins to the labeled probe was 
done by incubating 50 µg nuclear proteins with 50,000 cpm of labeled probe for 30 min at 
room temperature in a binding buffer [2 mM HEPES, 50 mM KCl, 2 mM EDTA, 10% 
glycerol, and 1% BSA (wt/vol)] in the presence of 2 µg poly(dI-dC) (Sigma) in a final 
reaction volume of 40 µL. For quantitative NFĸB p65 DNA binding, 10µg of nuclear protein 
was assayed for the presence of activated p65 by ELISA using antibodies specific for 
activated p65 following binding to NFκB consensus sequence (TransAM Active Motif). 
Statistical analyses. Data were tested for normality and analyzed using the mixed-
model analysis with diet and genotype considered fixed effects, and the time dietary 
treatments were implemented for subgroups as a random effect.  Significant interactions of 
main effects are indicated as Diet*Genotype effects.  All indicated P-values were two-tailed 
and Bonferroni corrected. Differences were considered significant at P < 0.05 and a tendency 
at P < 0.10. Values are presented as least squares (LS) means ± SEM.   
Results 
 
Tlr4 deficiency protects mice from increased adiposity caused by consumption of a 
diet high in saturated fat, without reducing caloric intake.  We examined whether the fatty 
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acid composition of the diet influenced the obesigenic effect of high fat diets in male Tlr4 
mutant (10ScN) and normal (10J) mice. Regardless of diet, 10ScN mice weighed on average 
3.8 g less than 10J mice after 16 weeks on the experimental diets (Genotype, P<0.0001, 
Figure 3A).  Furthermore, the HFC diet increased body weight in both genotypes (Diet, 
P<0.0001), but average weekly energy intake (Figure 3B) was reduced by the HFC diet 
(Diet, P<0.0001).  Additionally, epididymal fat pad weight was increased by the HFC diet in 
both genotypes.  However, only the mice lacking Tlr4 were protected against the obesigenic 
effect of the HFP diet (Figure 3C, Diet*Genotype, P=0.05).  Similar results were obtained for 
epididymal adipocyte size (Figure 3D) in that all mice fed the HFC diet had larger cells, but 
only the normal strain fed the HFP diet had enlarged cells vs. the LFC (Diet*Genotype, 
P=0.05).  
To confirm diet-induced changes in fatty acid profiles of epididymal adipose tissue, 
we measured SFA, n-3, and n-6 fatty acid contents (Table 3). As expected, relative to the 
LFC and HFP diets, both palmitate and total SFA were reduced in mice fed the HFC diet 
(Diet, P<0.002), and n-3 fatty acids (docosahexaenoic acid and eicosapentaenoic acid) were 
lower in mice fed the HFP diet (Diet, P<0.002). Furthermore, the n-6 fatty acid content was 
higher in mutant mice (Genotype, P<0.005) and was also reduced by the HFP diet (Diet, 
P<0.03).  However, the effects of diet and genotype on n-3 and n-6 fatty acid contents were 
not sufficient to alter the n-6 to n-3 ratio in this particular adipose depot. 
Tlr4 deficiency improved markers of insulin sensitivity and inflammation. To gain 
insight into the effect of high fat intake on insulin sensitivity in Tlr4 deficient mice, we 
measured fasting serum glucose (Figure 4A) and insulin (Figure 4B) following 16 weeks on 
experimental diets.  Glucose concentrations were lower in the mutant strain (Genotype, 
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P=0.0068), and were reduced in both genotypes fed either high fat diet (Diet, P=0.0014). 
Insulin concentrations were also lower in Tlr4 mutant mice (Genotype, P<0.0001).  
Alternatively, the HFC diet nearly doubled serum insulin in these mice, but this response 
only approached significance (Diet, P=0.111), and there was no effect on the normal strain 
(Diet*Genotype, P=0.15). However, these differences resulted in lower glucose to insulin 
ratios (GIR) in mutant mice fed the HFC diet as compared with the LFC or HFP diets, and 
the normal 10J mice had similar GIR, regardless of diet (Diet*Genotype, P=0.028).  
 We then measured several markers of inflammation that have been associated with 
obesity. The serum concentration of leptin was greater in all mice fed the HFC diet (Diet, 
P=0.0004, Figure 4D), and serum adiponectin was lower in the mutant strain (Genotype, 
P=0.043, Figure 4E). Additionally, the HFC diet increased serum adiponectin relative to the 
control and HFP diets, but only in the mutant strain (Genotype*Diet, P=0.031). Serum MCP-
1 was seven-fold higher in 10J vs. mutant mice (Genotype, P<0.0001, Figure 4F), but was 
not influenced by diet in either genotype. 
 Obesity-induced inflammation in adipose tissue was differentially regulated by 
dietary SFA vs. UFA, and was partly ameliorated by Tlr4 deficiency. To determine if 
inflammatory markers were related to changes in adipose tissue, we quantified macrophage 
infiltration and measured several inflammatory markers in adipose tissue. The percentage of 
F4/80-positive cells (i.e., macrophages) in adipose tissue of 10J control mice was greater in 
mice fed either HF diet (Diet P<0.0001, Figure 5A).  Alternatively, Tlr4 deficiency 
attenuated the SFA-induced, but not HFC-mediated, macrophage accumulation in 10ScN 
mice (Genotype*Diet interaction P=0.0002). Furthermore, the greater percentage of F4/80 
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positive cells was associated with the formation of distinct crown-like structures (CLS) 
(Figure 4B).  
We then examined the mRNA abundance of selected proinflammatory chemokines 
and cytokines. MCP-1 expression was increased in the epididymal adipose tissue of 10J mice 
fed the high fat diets (Genotype*Diet, P=0.021, Figure 6A). There was also a trend for 
increased CCR2 transcript abundance in mice fed either HF diet (Diet, P=0.089, Figure 6B). 
Expression of the proinflammatory cytokines, TNFα (Figure 6C) and IL-6 (Figure 6D), were 
increased by over 2- and 3-fold in adipose tissue of mice fed the HFP diet (Diet, P=0.013 and 
P<0.0001, respectively). Furthermore, the magnitude of the increase in IL-6 was greater in 
mutant vs. normal mice fed the HFP diet (Genotype*Diet, P=0.074). Tlr2 expression was 
increased over 2-fold with diet-induced obesity, irrespective of genotype (Diet Effect, 
P=0.035, Figure 6E).  
To determine if the proinflammatory transcription factor NFĸB may be involved in 
adipose-specific inflammation, we utilized electrophoretic mobility shift assays as a 
qualitative assessment of NFĸB translocation. There was a marked reduction in the nuclear 
localization of NFĸB in Tlr4-deficient mice regardless of diet (Figure 7A). Similar 
quantitative results were obtained using a NFĸB p65 DNA binding ELISA, which indicated 
adipose tissue nuclear NFĸB concentration in mutant mice was 50% less than that in 10J 
mice (Genotype, P=0.0015, Figure 7B).  
Discussion 
 
The data presented herein establish a novel relationship between obesity and Tlr4. 
The absence of a functional Tlr4 due to the 74 kb deletion on chromosome 4 in the 10ScN 
strain selectively protects against the obesigenic effect of a diet high in SFA, but not that of 
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an isocaloric diet high in UFA in male 10ScN mice.  Although we did not quantify total body 
fat mass in this study, adipocyte size mirrored epididymal fat pad weights, and thus reinforce 
our conclusion that the absence of Tlr4 protected against diet-induced obesity (DIO), but 
only when the diet was based on SFA.  It is also important to note that this resistance to 
adipocyte hypertrophy occurred without a corresponding reduction in energy consumption, 
and is thus of metabolic origin, rather than a simple limitation in energy intake.  These 
findings may implicate energy expenditure, and this possibility and potential underlying 
mechanisms are currently under investigation.  Additionally, it is intriguing that recent 
findings indicated that the gut microbial population influences adipose accretion through 
effects on energy availability and regulation of the fasting-induced adipocyte factor (Fiaf).  
The Fiaf protein is a circulating lipoprotein lipase inhibitor expressed by the intestinal 
epithelium and adipocyte, and knockout models have shown that the absence of Fiaf 
protected against over accumulation of adipose tissue caused by introduction of a normal 
microbiota in germ-free mice (28).  Consequently, it seems possible that the absence of Tlr4 
precludes changes in the gut microbiota in response to SFA that would alter Fiaf expression 
and thereby influence triglyceride storage in adipocytes.     
Recent reports (22-25) have indicated mixed results with regards to DIO in Tlr4 
mutant or knockout mice.  Our results are consistent with those of Tsukumo et al. (25), who 
also used males, but from the C3H/HeJ model.  In contrast, Shi et al. (23) used females from 
a Tlr4 knockout model backcrossed with C57BL6J for six generations, and determined that 
these mice succumbed to DIO when fed a high-fat diet containing lard. Furthermore, Poggi et 
al. (24) reported heavier epididymal adipose weights and adipocyte hypertrophy in male 
C3H/HeJ mice consuming a high fat diet based on anhydrous milk fat, which likely varies 
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considerably in fatty acid composition.  Although the mechanisms underlying these disparate 
results are not yet apparent, Tsukumo et al. (25) suggested that metabolic and physiologic 
differences relating to strain and background are likely to be important factors, and our data 
clearly indicate a strong linkage between Tlr4 function, dietary fat source, and DIO.  Equally 
important, Cani et al. (29) provided convincing evidence that mice consuming a high fat diet 
containing both corn oil and lard had increased circulating concentration of bacterial 
lipopolysaccharide that triggered obesity and inflammation.  Because mice lacking the CD14 
co-receptor for Tlr4, which precludes formation of a functional Tlr4 complex, were resistant 
to this phenomenon, these researchers suggested that endotoxemia facilitated by dietary fat 
intake largely mediates the effects of a high fat diet on obesity and inflammation via a Tlr4-
mediated signaling pathway.  Collectively, the data substantiate the possibility that SFA 
promote obesity post-absorptively by direct activation of Tlr4, and (or) promote the uptake of 
gut-derived endotoxin, which also activates Tlr4 signaling.  Consequently, it will be of 
utmost importance in the future to establish the effects of specific Tlr4 mutations and 
knockout models on obesity with respect to specific dietary fat sources and fatty acid 
profiles. 
Chronic inflammation in adipose tissue is a co-morbidity of obesity that is strongly 
associated with the onset and progression of insulin resistance, and ultimately the transition 
to frank diabetes.  We have shown previously that treating cultured adipocytes with palmitate 
results in activation of NFĸB and proinflammatory cytokine expression and release into the 
culture media (30).  Furthermore, using in vivo and in vitro experiments, Shi et al. (23) 
determined that a functional Tlr4 is a requisite component of the proinflammatory effects of 
palmitate or SFA on adipocytes.  With respect to the present data, several points are notable.  
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First of all, the only inflammatory marker attenuated by the absence of Tlr4 was MCP-1.  
Whereas the high fat diets, irrespective of whether saturated or unsaturated in composition, 
resulted in increased MCP-1 expression in epididymal adipose tissue of normal mice, neither 
diet altered expression in mutant mice.  Furthermore, the expression of both IL-6 and TNFα 
were markedly increased by the HFP diet, irrespective of genotype, and chemokine (C-C 
motif) receptor 2 (CCR2) expression was increased by the high fat diets in both genotypes.  
These results indicate not only that some inflammatory responses to high fat diets may be 
mediated independently of Tlr4, at least at the mRNA level, but also that some responses to 
high fat intake occur whether the fat is comprised predominantly of SFA or UFA.  It should 
also be noted that even in the absence of epididymal adipose expansion and adipocyte 
hypertrophy in the mutant mice fed the HFP diet, both IL-6 and TNFα expression were 
increased.  This possibly indicated a metabolic component to the proinflammatory effects of 
saturated fatty acids in adipocytes, as we have suggested previously, because inhibition of 
fatty acyl Co-A synthase attenuates the activation of NFκB by palmitate, but exacerbates IL-
6 release into the culture media (30).  Finally, the absence of a functional Tlr4 not only 
precluded the adipocyte hypertrophy in mice fed the HFP diet, but also blocked infiltration of 
adipose tissue with macrophages.  This is consistent with the hypothesis that it is adipocyte 
hypertrophy that ultimately signals macrophage recruitment, and it is clear that this response 
does not depend on a functional Tlr4.  
The serum MCP-1 and adipose NFĸB data show a striking effect of genotype in that 
both were markedly depressed in the mutant mice, and were largely unresponsive to diet.  
Although serum MCP-1 concentration was barely measurable in mutant mice, MCP-1 
adipose tissue expression differed little from that of normal mice.  This perhaps indicated 
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that adipose tissue contributed little to circulating MCP-1 in these mice, but we cannot 
discount the possibility that the adipose concentration was sufficient to be of physiological 
significance.  In regard to nuclear localization of adipose NFĸB, both qualitative and 
quantitative assessments indicated that the nuclear content of this important transcription 
factor is significantly lower in mutant vs. normal mice with little effect of diet.  We have 
shown previously that the transcriptional activity of NFĸB in adipocytes can be uncoupled 
from proinflammatory cytokine responses (30), but it is perhaps important that Shi et al. (23) 
noted a marked effect of dietary fat on NFĸB activity in a knockout model. 
In summary, our study indicated that the Tlr4 mutation in male 10ScN mice 
selectively blocked SFA-induced obesity, and that this response was associated with an 
absence of adipose infiltration with macrophages and improved markers of insulin sensitivity 
as reflected in the lower ratios of glucose to insulin.  These results point to a unique 
relationship between Tlr4 and saturated fatty acids, and underscore the potential for 
interactions between specific dietary fatty acids and Tlr4 mutations to impact the 
development of obesity and the associated inflammation.     
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Table 1.  Diet Composition 
Ingredient   Low-Fat Control (LFC)1 High-Fat Control (HFC)1 High-Fat Palmitate (HFP)1 
 
________________________ g/kg_______________________________  
Casein2   140    196    196 
Sucrose2   100    100    100 
Corn Starch2  455.692    88.192    88.192 
Maltodextrin2  155    155    155 
Soybean Oil2  50    360  
     Saturated  7.2    51.9  
          Palmitate  5.2    37.1  
     MUFA  11.7    83.9  
     PUFA  28.9    208.1  
Lard2           235 
     Saturated          92.2 
          Palmitate          55.9 
     MUFA          106 
     PUFA          26.4 
Palmitate3          125 
Cholesterol2      1.5    1.5 
Cellulose2  50    50    50 
Vitamin Mix2  10    10    10 
Mineral Mix2  35    35    35 
Choline Bitartrate2 2.5    2.5    2.5 
L-Cysteine2  1.8    1.8    1.8 
THBQ2   0.008    0.008    0.008 
Total (g)  1000    1000    1000 
Protein (kcal)  567.2    791.2    791.2 CHO (kcal)  2842.768   1372.768   1372.768 
Fat (kcal)  450    3240    3240 
Saturated (kcal)  64.8    467.1    1954.8 
Palmitate (kcal)  46.8    333.9    1628.1 
MUFA (kcal)  105.3    755.1    954 
PUFA (kcal)  260.1    1872.9    237.6 
Density (kcal/g)  3.86    5.40    5.40 
1. Adapted from AIN-93M Diet    2. Harlan Teklad, Madison, WI"    
3. Nu-Check Prep, Inc., Elysian, MN"    
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Table 2.  Primer Sequences for Quantitative Real-Time Polymerase Chain Reaction  
 
Target    Forward Primer   Reverse Primer   
 
Beta-Actin  TGAGAGGGAAATCGTGCGTGACAT    ACCGCTCGTTGCCAATAGTGATGA 
Toll-like receptor-4 CCGCTCTGGCATCATCTTCATTGT       TCCTCCCATTCCAGGTAGGTGTTT 
Toll-like receptor-2 TCCCTTGACATCAGCAGGAACACT     GCAGCCGAGGCAAGAACAAAGAA 
Monocyte  CCAAGAAGGAATGGGTCCAGACAT   ACAGAAGTGCTTGAGGTGGTTGTG 
Chemoattractant Protein-1 
Chemokine (C-C Motif) ACTGCATCTGCCCTAAGGTCTTCA     GAAGTGCTTGAGGTGGTTGTGGAA 
Receptor 2 
Tumor necrosis factor-α CCAACGGCATGGATCTCAAAGACA   AGATAGCAAATCGGCTGACGGTGT 
Interleukin-6  TCCAGTTGCCTTCTTGGGACTGAT     AGCCTCCGACTTGTGAAGTGGTAT 
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Table 3.  Adipose tissue fatty acid profiles in normal and Tlr4 mutant mice fed low fat 
control, high fat control, and high fat-palmitate diets for 16 weeks  
 
Diet    Genotype   n     Palmitate    SFA  n3 FA    n6 FA   n6:n3 Ratio 
 
        ________________________g/100g________________________        
LFCa    10ScN  6     31.35 ± 3.47    33.68 ± 3.38 0.49 ± 1.00  41.56 ± 6.19 60.40 ± 28.22  
HFCa   10ScN  6     18.10 ± 3.22    19.84 ± 3.16 2.23 ± 0.98 49.51 ± 5.58 77.63 ± 27.05 
HFPa   10ScN  6     28.45 ± 3.18    30.61 ± 3.10 n.d.  36.59 ± 5.63 85.99 ± 26.36 
LFCa   10J  6     24.02 ± 2.94    26.53 ± 2.88 2.17 ± 0.95 31.05 ± 5.18   27.88 ± 24.67 
HFCa   10J  6     17.64 ± 3.13    19.75 ± 3.06 2.16 ± 0.96 32.42 ± 5.57 66.68 ± 25.77 
HFPa   10J  6     29.76 ± 3.19    32.15 ± 3.12 0.53 ± 0.99 15.18 ± 5.53 35.62 ± 26.92 
 
Main Effects 
Genotype        P = 0.48  P = 0.52  P = 0.18  P = 0.0055 P = 0.48  
Diet         P = 0.0026 P = 0.0014 P = 0.0025 P = 0.033 P = 0.21 
 
Interaction 
Diet*Genotype        P = 0.32 P = 0.29  P = 0.22  P = 0.61  P = 0.67  
 
aLow Fat Control (LFC), High Fat Control (HFC), and High Fat Palmitate (HFP) diets
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Figure 3. Tlr4 deficiency protects mice from increased adiposity due to consumption of a 
diet high in saturated fat.  
All measures were taken after 16 weeks on experimental diets (n = 25 unless noted 
otherwise).  (A) Body weight of 10ScN (white bars) and 10J (black bars) mice (Diet effect 
P<0.0001, Genotype effect, P<0.0001, Diet*Genotype interaction P=0.84). (B) Average 
weekly energy intake (kcal/week) of 10ScN and 10J mice (Diet effect P<0.0001, Genotype 
effect P=0.34, Diet*Genotype interaction P=0.94). (C) Epididymal fat pad weight of 10ScN 
and 10J mice (Diet effect P<0.0001, Genotype effect P<0.0001, Diet*Genotype interaction 
P=0.058). (D) Adipocyte size (µm2) of 10ScN and 10J mice (n = 6, Diet effect P=0.0079, 
Genotype effect P<0.0001, Diet*Genotype interaction P=0.052). All displayed values 
represent LS means ± SEM for Diet*Genotype interaction. When interaction term was 
P<0.15, Bonferroni correction was used to determine significant difference between means as 
indicated by different letters. Significant main effects (Genotype and Diet) were also 
indicated by * (Genotype effect) and # (Diet effect) over LS means.
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Figure 4. Tlr4 deficiency improved markers of insulin sensitivity and inflammation in mice 
fed a diet high in saturated fat. 
 
All measures were taken after 16 weeks on experimental diets (n = 10 unless noted 
otherwise). (A) Serum glucose (Diet effect P=0.0014, Genotype effect P=0.0068, 
Diet*Genotype interaction P=0.57), (B) serum insulin (Diet effect P=0.111, Genotype effect 
P<0.0001, Diet*Genotype interaction P=0.15), (C) glucose to insulin ratio (Diet effect 
P=0.038, Genotype effect P<0.0001, Diet*Genotype interaction P=0.028), (D) serum leptin 
(Diet effect P=0.0004, Genotype effect P=0.50, Diet*Genotype interaction P=0.15), (E) 
serum adiponectin (Diet effect P=0.25, Genotype effect P=0.043, Diet*Genotype interaction 
P=0.11), and (F) serum MCP-1 (Diet effect P=0.96, Genotype effect P<0.0001, 
Diet*Genotype interaction P=0.78) were measured in 10ScN (white bars) and 10J (black 
bars) mice following 16 weeks on diet. All displayed values represent LS means ± SEM for 
Diet*Genotype interaction. When interaction term was P<0.15, Bonferroni correction was 
used to determine significant difference between means as indicated by different letters. 
Significant main effects (genotype and diet) were also indicated by * (genotype effect) and # 
(diet effect) over LS means. 
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Figure 5. Accumulation of F4/80-positive macrophages is attenuated in adipose tissue of 
high Tlr4 deficient (10ScN) mice fed the HFP diet. 
 
Five micron sections were cut at 50µm intervals and mounted on glass slides, deparaffinized 
in xylene, and stained for expression of F4/80 with monoclonal antibody. Adipose sections 
were visualized under 40X magnification. (A) Percent F4/80 positive cells (n = 5, genotype 
effect P=0.65, diet effect P=0<0.0001, genotype*diet interaction P=0.0002), were measured 
in 10ScN (white bars) and 10J (black bars) mice following 16 weeks on diet. All displayed 
values represent LS means ± SEM for Diet*Genotype interaction. When interaction term was 
P<0.15, Bonferroni correction was used to determine significant difference between means as 
indicated by different letters. Significant main effects (genotype and diet) were also indicated 
by * (genotype effect) and # (diet effect) over LS means. 
 (B) Representative images from 10ScN and 10J mice fed low fat (LFC), high fat (HFC), or 
HFP diet. 
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Figure 6. Adipose tissue inflammatory gene expression in Tlr4 deficient (10ScN) mice is 
differentially regulated in response to the HFP diet. 
 
All measures were taken after 16 weeks on experimental diets (n = 6 unless noted otherwise). 
(A) MCP-1 (Diet effect P=0.70, Genotype effect P=0.31, Diet*Genotype interaction 
P=0.021), (B) CCR2 (Diet effect P=0.089, Genotype effect P=0.33, Diet*Genotype  
interaction P=0.35), (C) TNFα (Diet effect P=0. 013, Genotype effect P=0.56, 
Diet*Genotype interaction P=0.93), (D) IL-6 (Diet effect P<0.0001, Genotype effect P=0.98, 
Diet*Genotype interaction P=0.074), and (E) Tlr2 (Diet effect P=0. 035, Genotype effect 
P=0.45, Diet*Genotype interaction P=0.65) were measured in 10ScN (white bars) and 10J 
(black bars) mice following 16 weeks on diet. All displayed values represent LS means ± 
SEM for Diet*Genotype interaction. When interaction term was P<0.15, Bonferroni 
correction was used to determine significant difference between means as indicated by 
different letters. Significant main effects (genotype and diet) were also indicated by * 
(genotype effect) and # (diet effect) over LS means. 
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Figure 7. Tlr4 deficiency attenuates NFκB activation in adipose tissue of Tlr4 deficient 
(10ScN) mice. 
Animals were fasted 6-8h and epididymal fat pad was collected. Nuclear extracts were 
obtained from adipose tissue and subsequently used for (A) NFκB EMSA, each lane 
represents an individual sample (n = 2). (B) NFĸB p65 DNA binding ELISA. Nuclear 
extracts were used to quantify NFκB DNA binding; 10ScN (white bars) and 10J (black bars) 
(n = 4, Diet effect P=0.39, Genotype effect P=0.0015, Diet*Genotype interaction P=0.43). 
All displayed values represent LS means ± SEM for Diet*Genotype interaction. When 
interaction term was P<0.15, Bonferroni correction was used to determine significant 
difference between means as indicated by different letters. Significant main effects (genotype 
and diet) were also indicated by * (genotype effect) and # (diet effect) over LS means.
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CHAPTER 4.  THE C-JUN N-TERMINAL KINASE MEDIATES THE INDUCTION 
OF OXIDATIVE STRESS AND INSULIN RESISTANCE BY PALMITATE AND 
TOLL-LIKE RECEPTOR 2 AND 4 LIGANDS IN 3T3-L1 ADIPOCYTES 
(Submitted to Hormone & Metabolic Research) 
 
Abstract 
 
Saturated fatty acids (SFAs) are known to induce inflammation and insulin resistance 
in adipocytes through toll-like receptor-4 (Tlr4) signaling, but the mechanisms are not well 
delineated.  Furthermore, the potential roles of Tlr2 and the c-jun N-terminal kinase (JNK) in 
inflammation in adipocytes have not been investigated.  We demonstrated that palmitate, 
lipopolysaccharide (LPS), and the toll-like receptor-2 (Tlr2) agonist, zymosan A (ZymA), 
induced insulin resistance in a time-and dose-dependent manner in 3T3-L1 adipocytes. 
Corresponding with the reduction of insulin sensitivity was an increased expression of IL-6, 
as well as activation of the proinflammatory transcription factors, nuclear factor kappa B 
(NFκB) and activator protein-1 (AP-1). Reactive oxygen species (ROS) accumulation was 
also observed in palmitate and Tlr agonist treated adipocytes. The JNK inhibitor, SP600125, 
attenuated insulin resistance mediated by SFA and Tlr agonists, which corresponded with a 
diminished proinflammatory response and reduced ROS accumulation. Collectively, these 
results demonstrated Tlr2 involvement in adipocyte inflammation and therefore implicated 
the receptor as a potential target for SFA. Moreover, activation of JNK also appeared to be 
essential to Tlr2-, as well as Tlr4-, induced insulin resistance and oxidative stress. 
Introduction 
 
Adipose tissue (AT) from obese individuals shows activation of several distinct 
inflammatory pathways, including those of NFκB and JNK (1,2). These proinflammatory 
signals stimulate production of cytokines and chemokines, including interleukin-6 (IL-6) and 
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monocyte chemotactic protein-1 (MCP-1), and thereby contribute to the systemic 
inflammation common in obesity (3,4).  Importantly, obesity-induced inflammation in 
humans is associated with insulin resistance and an increased risk of diabetes mellitus (DM) 
(1,2,5). These strong associations between obesity, inflammation, and insulin resistance 
implicate the adipocyte as an important link in the development of DM. 
Saturated fatty acids (SFA) activate inflammatory pathways and cause insulin resistance in 
myocytes (6-9), macrophages (10), and adipocytes (11). Furthermore, increased lipolytic 
rates in hypertrophied adipocytes result in greater release of non-esterified fatty acids 
(NEFAs), which can augment the inflammatory response of AT through the activation of 
neighboring macrophages and adipocytes (10). NEFAs are also implicated in the production 
of ROS and the ensuing oxidative stress (12). In the obese state, this increased flux of NEFA 
stimulates ROS production, which leads to impaired insulin signaling (13,14).  
 The molecular mechanisms involved in NEFA-induced inflammation, oxidative 
stress, and insulin resistance may involve several distinct pathways.  In primary myocytes 
and hepatocytes,  NFκB and AP-1 signaling are critical (9,15). Tlr4 activation was also 
implicated in SFA-induced inflammation and insulin resistance (3,16-20). LPS, a potent 
ligand for Tlr4, induces inflammation through JNK/AP-1 and NFκB signaling pathways in 
several cell types (21-25). Recently, Shi and colleagues (3) reported an attenuation of lipid-
induced NFκB activation and insulin resistance in AT of Tlr4 knockout mice. Several 
additional studies (18,19,26,27) have confirmed that Tlr4 deficiency protects animals from 
obesity-induced inflammation and insulin resistance. Moreover, we recently demonstrated 
that Tlr4 deficient 10ScN mice, were specifically protected from SFA-induced adiposity and 
that they have reduced macrophage accumulation in AT (28). In contrast, the pro-
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inflammatory cytokines IL-6 and TNFα were elevated in AT of 10ScN mice fed the same 
SFA-diet. These data suggest that whereas Tlr4 signaling plays a considerable role in SFA-
induced inflammation and adiposity, pro-inflammatory pathways independent of Tlr4 must 
also exist.   
Like Tlr4, the Tlr2 receptor is increased in AT of obese and diabetic individuals 
(22,29). Adipocytes of mice fed a high fat diet have greater expression of this pattern 
recognition receptor (30). It is known that SFA signal through Tlr2 and activate IKKβ/NFκB 
and JNK/AP-1 pathways in myotubes and epithelial cells, respectively (31-33). Additionally, 
Senn (31) reported that palmitate-induced insulin resistance in C2C12 myotubes is attenuated 
when Tlr2 signaling is blocked by either siRNA or a neutralizing antibody. ROS 
accumulation after vascular injury is also blunted in Tlr2 knockout mice (34). Thus, 
considering the recognized involvement of Tlr2 in oxidative stress and insulin resistance in 
multiple cell types, we hypothesized that Tlr2 agonists Zymosan A (ZymA) and palmitate 
would activate inflammatory signaling in the adipocyte and thereby promote inflammation, 
oxidative stress, and insulin resistance as observed in obesity.   
The data presented herein indicated clearly that ZymA and palmitate activate JNK 
and cause NFκB and AP-1 nuclear translocation and proinflammatory cytokine production. 
Furthermore, inhibition of JNK blocked Tlr2 and Tlr4 agonist-induced ROS and insulin 
resistance in adipocytes. These data also provide novel evidence supporting a potential role 
for Tlr2 in dietary SFA-induced inflammation and insulin resistance. 
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Materials and Methods 
 
Cells and Reagents. 3T3-L1 preadipocytes were obtained from American Type 
Culture Collection (Manassas, VA, USA).  All reagents were obtained from Sigma-Aldrich 
(St. Louis, MO, USA) unless otherwise specified.  
Cell Culture and Treatment. 3T3-L1 preadipocytes were grown in 5% CO2 in low 
glucose (5.5 mM) DMEM containing 10% fetal bovine serum (FBS; Atlanta Biologicals, 
GA, USA) in the presence of a 1% penicillin/streptomycin mixture (growth media). At 2 d 
post-confluence (0 d), cells were induced to differentiate with medium containing 10% FBS, 
1.7 µM insulin, 0.4 mM biotin, 1.0 µM dexamethasone, and 1.5 mM isobutylmethylxanthine 
for 48 h. Thereafter, fresh growth media supplemented with 1.7 µM insulin was added for 2-
3 d followed by insulin-free growth media for the remaining culture period. At 10-12 d, cells 
were cultured in medium containing 10% FBS, 0.3 µM bovine serum albumin (BSA), and 
0.1% methanol with one or a combination of the following treatments: 0.5 mM sodium 
palmitate, 10 µg/mL LPS from Escherichia coli 055:B5, 20 µg/mL ZymA from 
Saccharomyces cerevisiae, and 20 µM SP600125. At 24 h, medium was collected and fresh 
medium with 0.1% FBS was added with indicated treatments. 
Quantitative real-time PCR. Total RNA was extracted from cells using a 
commercially available acid-phenol reagent (TRIzol, Invitrogen, Carlsbad, CA, USA). 
Potential DNase contamination was removed with DNase-freeTM (Ambion, Foster City, CA, 
USA). First-strand cDNA was synthesized using SuperScript® III First-Strand Synthesis 
System for RT-PCR (Invitrogen, Carlsbad, CA, USA). Primer sequences used to detect β-
actin, Tlr4, Tlr2, MCP-1, and IL-6 are described elsewhere (28). Thermal cycling conditions 
for PCR reactions were 95°C for 3 min followed by 40 cycles of 95°C for 15 s, 60°C for 30 
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s, and 72°C for 30 s. Products amplified by these primers were cloned into pGEMT vector 
(Promega, Madison, WI, USA) and sequenced to confirm transcript identity. Real-time PCR 
reactions were carried out with an iCycler using the IQTM SYBR Green Super Mix kit (Bio-
Rad, Hercules, CA, USA). The abundance of each transcript was calculated by regression 
against the standard curve generated on the same plate with the respective plasmid. 
Expression levels of genes of interest were normalized to β-actin and are reported as fold 
change based on log starting quantity. 
Analysis of Metabolic Parameters. Total nitrite and IL-6 concentrations in medium 
were determined using commercially available ELISA kits (Biovision, Mountain View, CA, 
USA and R&D Systems, Minneapolis, MN, USA, respectively). Glycerol release was 
measured as previously described (35). 
Western Blot Analysis. Cells were grown in 6 well tissue culture plates, and treated as 
described above.  To harvest protein for analysis, media from cells was aspirated, and cells 
were rinsed once with ice cold PBS.  Lysis buffer (10 mM Hepes pH 2.5, 20 mM Tris-HCl 
pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerolphosphate, 1 mM sodium orthovandate, 1 µg/mL leupetin, 1 
µg/mL aprotinin, 1 µg/mL pepstatin, and 1 mM PMSF) was added to each well of cells, 
which were then scraped from the plate. Cell protein lysates were resolved by electrophoresis 
using 10% SDS–polyacrylamide gels and transferred to a nitrocellulose membrane for 
western blot analyses. The membrane was blocked with 5% skim milk in tris buffered saline 
(TBS) for 1 h at room temperature, and then incubated with phospho-SAPK/JNK or 
SAPK/JNK monoclonal antibody (Cell Signaling Technology, Danvers, MA, USA) 
overnight at 4°C. After washing three times with TBST (0.05% Tween 20, 50 mM Tris–HCl, 
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pH 7.5, and 150 mM NaCl) for 15 min, the membrane was incubated for 1 h with anti-rabbit 
IgG secondary antibody conjugated with horseradish peroxidase. The signal was detected 
using the Phototope®-HRP Western Blot Detection System (Cell Signaling Technology, 
Danvers, MA, USA).  
NFĸB and AP-1 Electrophoretic Mobility Shift Assay (EMSA). Nuclear extracts for 
mobility shift assay reagents were prepared and validated as previously described (36). 
Briefly, the consensus NF-κB and AP-1 oligonucleotides (Santa Cruz, CA, USA) were end-
labeled with [-32P] ATP (PerkinElmer, Waltham, MA, USA) using T4 polynucleotide kinase 
(Santa Cruz, Santa Cruz, CA, USA). 10-30 µg of nuclear proteins were incubated with 
50,000 cpm of labeled probe for 30 min at room temperature in binding buffer [2 mM 
HEPES, 50 mM KCl, 2 mM EDTA, 10% glycerol, and 1% BSA (wt/vol)] with 2 µg poly(dI-
dC) in a total reaction volume of 40 µL. Probe-protein complexes were resolved by 
electrophoresis, and the gel was transferred to nitrocellulose and dried.   
Intracellular ROS Accumulation Assay. 30 µM of carboxy-H2DCFDA (DCF; 
Invitrogen, Carlsbad, CA, USA) was added to 1X Kreb’s Ringer Buffer (KRB; 12 mM 
HEPES, pH 7.4, 121 mM NaCl, 4.9 mM KCl, 1.2 mM MgSO4, 0.33 mM CaCl2). Cells were 
then incubated for 45 min at 37°C, after which medium was aspirated and cells washed three 
times with warm phosphate buffered saline (PBS). Culture plates were immediately read 
using a fluorescent plate reader (SpectraMax M5, Molecular Devices, Sunnyvale, CA, USA) 
with 435 nm excitation and 550 nm emission wavelengths, respectively. Fluorescence was 
normalized to total protein as determined with the bicinchoninic acid assay (BCA; Pierce, 
Rockford, IL, USA). Data are presented as percent of control. 
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2-Deoxyglucose (DG) Uptake. Cells were incubated with or without 5 µM 
cytochalasin B and with 100 nM insulin for 30 or 10 min at 37˚C, respectively, in 1X Krebs 
Ringer buffer (KRB). Non-insulin stimulated control cells were treated identically. Cell 
media was then supplemented with 0.5 µCi/mL [3-H]-2-DG and 120 µM non-labeled 2-DG 
and cells were incubated for an additional 25 min. Glucose uptake was terminated by 
aspiration of media.  Thereafter, the cells were washed with 1X KRB and lysed with 0.1 N 
NaOH. Cell lysates were used to determine 2-DG uptake via scintillation counting.  Uptake 
was normalized to total lysate protein as determined by BCA assay. Data are presented as 
fold change of insulin-stimulated controls. 
Statistical analyses. Data were tested for normality and analyzed using the mixed-
model analysis. Treatment was considered the fixed effect and experimental repetition the 
random effect. The main effects (treatment and replicate) were tested against the treatment x 
replicate interaction term. When protected by a significant F-test, mean separation was 
accomplished using the least-squares mean separation (pdiff) procedure. Differences were 
considered significant at P < 0.05.  Tendencies were defined at P < 0.10.   
Results 
 
Time dependent induction of insulin resistance by palmitate, ZymA, and LPS in 3T3-
L1 adipocytes. Based on previous data, we investigated the ability of LPS and palmitate 
compounds (at previously studied doses) to mediate insulin resistance in a time dependent 
manner. Here we demonstrated that palmitate treatment reduced insulin-stimulated 2-DG 
uptake beginning at 12 h and continuing through 48 h (Fig. 8, P<0.05). Alternatively, ZymA 
and LPS only inhibited insulin-stimulated 2-DG uptake following 48 h of treatment 
(P=0.0022 and P=0.0048, respectively). Therefore, we treated adipocytes for 48 h with 
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palmitate, ZymA, or LPS in order to study mechanisms involved in the development of 
insulin resistance. 
ZymA induced inflammation and oxidative stress in adipocytes in a manner similar to 
that caused by palmitate and (or) LPS. As shown in Table 4, the Tlr2 agonist, ZymA also 
caused a 2-fold increase in IL-6 gene expression (P=0.05) which corresponded with a greater 
than 10-fold increase in media IL-6 content (P<0.0001, Table 4).  Consistent with prior 
findings, palmitate resulted in an approximate 4-fold increase in IL-6 gene expression 
(P<0.0001) and 30-fold increase in IL-6 media content (P<0.0001). We further evaluated the 
inflammatory response in adipocytes by quantifying the expression of the pro-inflammatory 
chemokine, MCP-1. As with palmitate and LPS, ZymA increased MCP-1 expression vs. 
control cells (P<0.0001, Table 4) with a near 2-fold greater transcript abundance. The 
expression of Tlr2 and Tlr4 were evaluated to assess potential feedback regulation of Tlr 
ligands on their respective receptors. Although Tlr2 expression was induced by all treatments 
(P<0.0001, Table 4), Tlr4 was largely unresponsive to these pro-inflammatory mediators 
(Table 4), with the exception that LPS tended to reduce expression of Tlr4 (P=0.09). To 
investigate the roles that Tlr ligands play in the accumulation of ROS, we measured several 
markers of oxidative stress and ROS production. First, we quantified expression of the 
inducible nitric oxide synthase gene, and found that palmitate, LPS, and ZymA all caused a 
5-fold increase in iNOS expression (P<0.0001, Table 5).  Next, we assessed ROS 
accumulation, and demonstrated that all three ligands caused a 50% increase in intracellular 
ROS (P<0.01, Table 5). However, an increase in media nitrite concentrations (25%, P=0.008, 
Table 5), indicative of extracellular oxidative stress, was apparent only in response to 
palmitate.  
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NFκB, AP-1, and JNK were activated by palmitate, ZymA and LPS in adipocytes. We 
next studied potential mechanisms underlying the pro-inflammatory effects of palmitate and 
the classic Tlr ligands. JNK has been implicated previously in proinflammatory signaling in 
adipocytes (37,38), and consequently, we quantified phosphorylation of JNK1 (Thr183, 46 
kDa) and JNK2 (Tyr185, 54 kDa) as an indicator of activation in cells treated with palmitate, 
LPS, and ZymA. All three pro-inflammatory mediators significantly increased JNK 
phosphorylation (P<0.05, Fig. 9A-B). Activation of JNK is known to stimulate the activity of 
the pro-inflammatory transcription factors, NFκB and AP-1. After 48 h, there was increased 
activation of NFκB by palmitate, LPS, and ZymA (Fig. 9C). Consistent with previous results, 
the LPS treatment had the most pronounced effect on NFκB activation under the applied 
experimental conditions. Likewise, AP-1 activation was also increased by all of the pro-
inflammatory mediators (Fig. 9D), and was greatest in cells exposed to ZymA.   
Inhibition of JNK attenuated palmitate- and Tlr ligand-induced inflammation, 
oxidative stress, and insulin resistance in adipocytes. Our findings indicated that palmitate, 
LPS, and ZymA all induced JNK activation.  Hence, we sought to determine whether 
inhibition of JNK would attenuate the inflammatory, oxidative, and insulin resistance 
responses in adipocytes. We first confirmed that there was a reduction of JNK 
phosphorylation by SP600125 in our adipocyte model.  As compared with the non-inhibitor 
control cells, there was a 22% (P=0.045), 45% (P=0.0005), and 33% (P=0.0045) reduction in 
palmitate-, LPS- and ZymA-induced JNK activation, respectively, when cells were also 
incubated with the SP600125 inhibitor (Fig. 10A-B). Furthermore, as shown in Fig. 10C, 
inhibition of JNK completely abrogated the effect of palmitate on IL-6 expression 
(P<0.0001), and attenuated the induction by LPS and ZymA. In contrast, inhibition of JNK 
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did not alter the effects of LPS or ZymA on MCP-1, Tlr2, or Tlr4 expression (Fig. 10D). 
However, there was a small (approximately 20%), but significant, decrease in palmitate-
induced MCP-1 (P=0.023), Tlr2 (P<0.0001, Fig. 10E), and Tlr4 (P=0.0014, Fig. 10F).  
To establish whether the blunted inflammatory responses caused by inhibition of JNK 
were associated with changes in NFκB and AP-1 activation, adipocytes were treated with 
LPS, palmitate, or ZymA in the presence or absence of SP600125. The JNK inhibitor 
reduced the induction of NFκB by all three pro-inflammatory mediators (Fig. 10A), but this 
was qualitatively more pronounced for palmitate. Conversely, inhibition of JNK only 
reduced activation of AP-1 in cells stimulated with palmitate or ZymA (Fig. 10B).  
JNK mediated the insulin resistance caused by palmitate and Tlr ligands.  There was 
only a small (non-significant) reduction in LPS- and ZymA-induced iNOS expression in the 
presence of the JNK inhibitor (Fig. 10C). Conversely, palmitate-induced iNOS expression 
was dramatically reduced (over 60%, P<0.0001) with inhibitor. Furthermore, ROS 
accumulation (Fig. 10D), as measured by DCF fluorescence, was reduced by 50-60% 
(P<0.0001) for cells stimulated with palmitate or Tlr agonist.  To determine if the attenuated 
ROS accumulation impacted insulin sensitivity, we assessed glucose uptake using 2-DG 
(Fig. 10E). Insulin-stimulated glucose uptake was improved over 40% in cells stimulated 
with palmitate (P=0.0026), LPS (P=0.0018), or ZymA (P<0.0001) when JNK was blocked by 
the inhibitor.  
Discussion 
 
The data presented herein indicated several important points regarding the regulation 
of inflammation and insulin sensitivity in adipocytes by palmitate and Tlr ligands.  First of 
all, we showed that activation of Tlr2 resulted in a pro-inflammatory response and insulin 
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resistance that bore marked similarity to responses caused by palmitate or activation of Tlr4 
by LPS.  Palmitate and both Tlr agonists resulted in increased nuclear localization of the 
NFκB and AP1 transcription factors, and caused increased expression of MCP-1, Tlr2, and 
iNOS, as well as increased ROS accumulation.  Furthermore, as with palmitate and LPS, 
activation of Tlr2 by ZymA activated JNK and attenuated the ability of insulin to stimulate 
glucose uptake (as determined with 2-DG).  
The importance of Tlr2 activation as a contributor to inflammation in adipose tissue 
in vivo has not yet been established, but Nguyen et al. (39) recently demonstrated that NEFA 
activation of JNK involves both Tlr2 and Tlr4 in RAW 264.7 macrophages.  The fact that 
Tlr2 is upregulated by palmitate, LPS, or ZymA, whereas Tlr4 is not, underscores the 
potential importance of signaling in adipose tissue via this receptor to obesity-linked 
inflammation. Furthermore, these receptors have a synergistic relationship in terms of 
activation of proinflammatory signaling. For instance, stimulation of Tlr4 leads to increased 
expression of Tlr2 and thus amplification of the inflammatory response (40). Moreover, the 
ability of these receptors to recognize similar ligands, including SFAs, suggests that Tlr2 and 
Tlr4 are major mediators of obesity-induced inflammation. In the present study, the more 
pronounced effect of palmitate may result from a combination of signaling through both of 
these innate immune receptors.  
Our second major finding pertains to the importance of JNK activity to ROS 
accumulation and insulin-stimulated glucose uptake.  Obesity-linked inflammation and 
oxidative stress contribute to the development of insulin resistance (12,37,41,42). Although 
the exact mechanism is not yet known, NEFA were associated with the generation of ROS in 
adipocytes (12). Lee and colleagues (43) recently demonstrated that a Tlr-JNK pathway 
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regulated ROS signaling in macrophages. Furthermore, Kaneto and colleagues (44) 
suggested that JNK mediates insulin resistance through generation of oxidative stress.  Our 
data show that palmitate, LPS, and ZymA all induce JNK phosphorylation (activation), iNOS 
expression and ROS accumulation in adipocytes.  Furthermore, the inhibitor used to disrupt 
activation of JNK not only blocked or attenuated the ability of palmitate, LPS and ZymA to 
stimulate phosphorylation of JNK, it also precluded the induction of ROS and the diminution 
in insulin-stimulated 2DG uptake by these pro-inflammatory factors.  
We recognize the inherent limitations of kinase inhibitors, including their low 
specificity. However, it should be noted that SP600125 is shown to have >20-fold selectivity 
for JNK compared to a range of other kinases (45).  Future experiments utilizing Tlr 
knockdown models will be necessary to further validate the specificity of SP6 to JNK. The 
redundancy of proinflammatory signals downstream of Tlr also suggest additional kinases 
may be involved in palmitate-, ZymA-, or LPS-induced inflammation. Regardless, our data 
strongly implicate JNK as a major determinant of ROS production in adipocytes, and 
confirm prior evidence (46) detailing the importance of ROS as determinants of insulin 
sensitivity in murine adipocytes.   
  Finally, we have identified the activation of AP-1 transcription factor as a 
component of the inflammatory response to palmitate, LPS, and ZymA, and presented initial 
evidence that activation of JNK may be required for activation of AP-1 by palmitate and 
ZymA, but not LPS. The fact that we showed a limited effect of JNK inhibition on LPS-
induced AP-1 activation may relate to distinct differences between Tlr4 and Tlr2 signaling 
(47). For instance, LPS and other Tlr4 agonists are capable of signaling through both 
MyD88-dependent and independent pathways, whereas Tlr2 ligands require the MyD88 
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adaptor protein in order to generate an effective proinflammatory response (48,49). In this 
study, activation of NFκB was induced by palmitate and both Tlr agonists. Moreover, the 
Tlr4 agonist, LPS, had the greatest increase in NFκB activation (Fig. 3C), whereas the Tlr2 
agonist, ZymA, had the greatest induction of AP-1 (Fig. 3D). Involvement of LPS in NFκB 
activation in adipocytes has been well documented (21,36). However, we have established 
herein that the Tlr2 agonist, ZymA, not only activates NFκB, but also induces AP-1 in 
adipocytes. The reduced ability of JNK inhibitor to fully inhibit LPS activation of AP-1 also 
suggested that JNK may be more involved in Tlr2 activation of AP-1. 
The in vivo activation of AP1 and NFκB in AT is likely a concerted process involving 
macrophages, preadipocytes, and adipocytes. The contribution of mature adipocytes to this 
process is unclear, but may be paramount as activation of these proinflammatory 
transcription factors promotes lipolysis (41), leading to increased NEFA and activation of Tlr 
signaling within adipocytes and neighboring cells. However, elucidating the contribution of 
different AT-based cells to Tlr2 and Tlr4 mediated inflammation will require further 
investigation.   
In conclusion, this study demonstrated involvement of Tlr2 agonists, ZymA, and 
palmitate, in adipocyte inflammation, oxidative stress, and insulin resistance. These data also 
indicated that JNK activation is essential to ZymA agonist induced NFκB and AP-1 
activation. Based on these data, we believe that Tlr2, in addition to Tlr4, is an important 
mediator of obesity-induced inflammation. Further insight into this relationship may provide 
potential therapeutic strategies to inhibit Tlr agonists for alleviating obesity-associated health 
complications. 
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Table 4.  Palmitate, ZymA, and LPS induced inflammation in 3T3-L1 adipocytes  
 
Treatment   IL-6  IL-6  MCP-1  Tlr2  Tlr4   
   Protein  Transcript Transcript Transcript Transcript 
    ____________________________Fold Change___________________________      
  
Control   1.00 ± 0.94a 1.19 ± 0.27a 1.12 ± 0.05a  1.16 ± 0.05a 1.29 ± 0.09ab  
Palmitate  29.5 ± 0.94c 4.02 ± 0.18c 1.42 ± 0.03b 1.54 ± 0.03b 1.48 ± 0.06b 
LPS   2.10 ± 0.94a 1.63 ± 0.21ab 1.59 ± 0.04c 1.68 ± 0.04c 1.04 ± 0.07a 
ZymA   13.1 ± 0.94b 1.93 ± 0.18b 1.80 ± 0.03d 1.70 ± 0.03c  1.31 ± 0.06b 
 
Treatment Effect  P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P = 0.0009 
 
a, b, c, d Significant difference between LS means indicated by different letters (P<0.05) 
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Table 5.  Palmitate, ZymA, and LPS induced inflammation in 3T3-L1 adipocytes 
 
Treatment   Total   NOS2   ROS    
   Nitrite   Transcript  Accumulation   
   ______________________Fold Change____________________        
Control   1.00 ± 0.06a  0.82 ± 0.23a   1.16 ± 0.16a   
Palmitate  1.05 ± 0.06b  3.15 ± 0.19b  1.89 ± 0.13b  
LPS   1.25 ± 0.06a  2.97 ± 0.19b  1.70 ± 0.16b  
ZymA   0.91 ± 0.06a  2.96 ± 0.16b  1.54 ± 0.15b   
 
Treatment Effect  P = 0.0036  P < 0.0001  P = 0.0027   
 
a, b, c Significant difference between LS means indicated by different letters (P<0.05) 
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Figure 8. Palmitate, ZymA, and LPS induced insulin resistance in 3T3-L1 adipocytes. 
 
10-12 d post-differentiated 3T3-L1 adipocytes were treated with 0.5 mM sodium palmitate, 
10 µg/mL LPS, or 20 µg/mL ZymA for 3, 6, 8, 12, 24, and 48 h. Insulin-stimulated 2-DG 
uptake was then determined (n = 8, Treatment effect P<0.0001, Time effect P<0.0001, 
Treatment*Diet effect P<0.0001).  A non-insulin stimulated contol was included for 
reference. Results are expressed as fold change versus insulin stimulated control and 
represent LS means ± SEM. When Treatment effect was significant (P<0.05), post-hoc t-test 
was used to determine significant difference between LS means as indicated by different 
letters. 
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Figure 9. Palmitate, ZymA, and LPS induced JNK phosphorylation and NFκB and AP-1 
nuclear translocation in 3T3-L1 adipocytes. 
 
10-12 d post-differentiated 3T3-L1 adipocytes were treated with 0.5 mM sodium palmitate, 
10 µg/mL LPS, or 20 µg/mL ZymA for 48 h (n= 4 unless noted otherwise). (A) 
Representative western blot showing phosphorylation of JNK (top panel) and total JNK 
levels (bottom panel). (B) Quantification of phosphorylated JNK by densitometry and 
expressed as fold change versus control (Treatment effect P=0.0089). Representative EMSA 
blot showing nuclear protein binding to labeled (C) NFκB and (D) AP-1 consensus 
sequences.  
  132
 
Figure 10. JNK inhibitor, SP600125, attenuated palmitate, ZymA, and LPS induced JNK 
phosphorylation and inflammation in 3T3-L1 adipocytes.  
 
10-12 d post-differentiated 3T3-L1 adipocytes were treated with 0.5 mM sodium palmitate, 
10 µg/mL LPS, or 20 µg/mL ZymA for 48 h (n=6-8 unless noted otherwise). (A) 
Representative western blot showing phosphorylation of JNK (top panel) and total JNK 
levels (bottom panel). (B) Quantification of phosphorylated JNK by densitometry (Treatment 
effect P<0.0001). (C) IL-6 gene expression (Treatment effect P<0.0001). (D) MCP-1 gene 
expression (Treatment effect P<0.0001). (E) Tlr2 gene expression (Treatment effect 
P<0.0001). (F) Tlr4 gene expression (Treatment effect P=0.0002). All displayed were 
expressed as fold change versus control and represent LS means ± SEM. When Treatment 
effect was significant (P<0.05), post-hoc t-test was used to determine significant difference 
between LS means as indicated by different letters.
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Figure 11. JNK inhibitor, SP600125, attenuated palmitate, ZymA, and LPS induced NFκB 
and AP-1 nuclear translocation, oxidative stress, and insulin resistance in 3T3-L1 
adipocytes.  
 
10-12 d post-differentiated 3T3-L1 adipocytes were treated with 0.5 mM sodium palmitate, 
10 µg/mL LPS, or 20 µg/mL ZymA for 48 h (n= 6-8 unless noted otherwise). Representative 
EMSA blot showing nuclear protein binding to labeled (A) NFκB and (B) AP-1 consensus 
sequences. (C) iNOS gene expression (Treatment effect P<0.0001). (D) DCF fluorescence 
(Treatment effect P<0.0001). (E) Insulin-stimulated 2-DG uptake (Treatment effect 
P<0.0001). All displayed values represent LS means ± SEM for Treatment effect. When 
Treatment effect was significant (P<0.05), post-hoc t-test was used to determine significant 
difference between LS means as indicated by different letters. 
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CHAPTER 5.  ABSENCE OF TLR2 AND TLR4 HIGH FAT DIET-INDUCED 
OBESITY AND ADIPOSE-SPECIFIC INFLAMMATION AND INSULIN 
RESISTANCE 
(To be submitted to Obesity) 
 
 
Abstract 
 
We previously demonstrated the involvement of toll-like receptor-4 (Tlr4) in saturated fatty 
acid (SFA)-induced inflammation and insulin resistance. However, less is known about toll-
like receptor-2 (Tlr2), which also recognizes SFA. To investigate the involvement of this 
receptor in diet-induced obesity, we utilized male Tlr2-/- mice and C57BL6J controls. We 
also compared 10Scn mice lacking functional Tlr4 and their respective control 10J.  Mice 
were fed a low fat (low-fat control (LFC)), high unsaturated fat (high-fat control (HFC)), or 
high saturated fat + palmitate (HFP) diet ad libitum for 16 weeks. Tlr2-/- mice were protected 
from DIO. However, unlike Tlr4 deficient 10ScN mice, there were no significant changes in 
body weight, energy intake, or lipid profile in Tlr2-/- mice fed any of the three diets as 
compared to their control. Serum markers of inflammation, including C-reactive protein, 
endotoxin, and monocyte chemotactic protein-1 (MCP-1) were lower in 10ScN mice fed 
HFP diet, whereas only MCP-1 levels were reduced in high fat fed Tlr2-/- mice. Transcript 
abundance of adipose markers of inflammation and oxidative stress, including tumor necrosis 
factor-α, interleukin-6, MCP-1, F4/80, and nitric oxide synthase-2, were attenuated by Tlr2 
and Tlr4 deficiency. Furthermore, these effects were more striking in HFP-fed mice. Blood 
glucose and serum insulin were lower in 10ScN mice, but not in Tlr2-/- mice. However, 
stromal vascular (SV) cells isolated from AT of Tlr2-/- had a marked increase in insulin 
sensitivity. These data indicated that Tlr2, as well as Tlr4, play a significant role in the 
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development of obesity-induced inflammation and insulin resistance, specifically in mice fed 
a HFP diet. 
Introduction 
 
Obesity-induced inflammation is associated with insulin resistance and an increased 
risk for diabetes mellitus (DM) (1-3). Obese individuals exhibit activation of several distinct 
inflammatory pathways, including nuclear factor kappa B (NFκB) and c-jun N-terminal 
kinase (JNK) (1,2), which are associated with macrophage infiltration in AT and stimulation 
of proinflammatory cytokines, such as monocyte chemotactic protein-1 (MCP-1) and 
interleukin-6 (IL-6). In addition, the incidence of DM is higher in obese versus healthy 
weight patients.  The strong association between obesity, inflammation, and insulin 
resistance suggests that adipose tissue (AT) plays a prominent role in their development. 
The underlying mechanism contributing to the proinflammatory response seen in AT 
of the obese is not fully elucidated, but may involve signaling through specific Tlrs. Shi and 
colleagues (4) reported attenuation of fatty acid (FA)-induced NFκB activation and insulin 
resistance in AT of Tlr4 null mice. Additional studies (5-8) have confirmed that Tlr4 
deficiency improved insulin sensitivity and lowered inflammation in diet-induced obesity 
(DIO). We previously demonstrated that 10ScN mice, which have a 74 kb deletion from 
chromosome 4 that precludes expression and production of Tlr4, were specifically protected 
from saturated fatty acid (SFA)-induced adiposity and AT-specific inflammation (9). 
However, Tlr-4 deficiency did not fully attenuate high fat diet-induced inflammation in AT. 
These data suggested that pathways independent of Tlr4 may also mediate obesity-induced 
inflammation and insulin resistance.  
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One potential candidate pathway is that of Tlr2, which is increased in AT of obese 
and diabetic individuals (10,11). Since SFA are reported to contribute to activation of Tlr2, it 
is a likely mediator of obesity-induced inflammation (12). Thus, the goal of this study was to 
test the hypothesis that the absence of Tlr2 expression attenuates systemic inflammation, 
improves insulin sensitivity, and decreases SFA-induced AT inflammation in DIO mice. 
Materials and Methods 
 
Animals and animal care. Male and female B6.129-Tlr2tm1Kir/J (Cat No. 004650; 
Tlr2-/-) mice and C57BL/10ScN mice (Cat No. 003752; 10ScN) derived from the C57BL/6J 
and C57BL/10J sublines, respectively, were obtained from Jackson Laboratories (Bar 
Harbor, ME), along with corresponding control male and female C57BL/6J (Cat No. 000664) 
and C57BL/10J (Cat No. 000665) mice. Breeding colonies were established for each 
genotype. Aberrant Tlr2 and Tlr4 expression was confirmed by real time PCR. At 6-8 weeks 
of age, male offspring were housed individually in a room with an automatically controlled 
12-hour light:dark cycle. Mice were acclimated to the cages and provided unlimited access to 
food and water.  
Animals from each genotype were randomly assigned to one of three experimental 
diets (n = 15/genotype/diet): 1) low fat control (LFC), high fat control (HFC), or high fat 
palmitate (HFP) for 16 weeks. Both high fat diets were semi-purified, powdered diets based 
on American Institute of Nutrition recommendations (13) that were modified to induce 
obesity by providing 60% of calories from lipids (Table 6). The high fat diets were identical 
except the source of fat used was either soybean oil in the HFC (Harlan Teklad) or a mixture 
of lard (Harlan Teklad) and purified palmitate (Nu-Check Prep, Inc.) in the HFP diet. The 
LFC diet contained 12% of calories from lipid. Food intake was measured daily and used to 
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calculate total energy intake. Mice were fasted overnight (6-8 h) and euthanized by CO2 
asphyxiation for blood and tissue collections. Blood was collected by heart puncture, placed 
on ice, and serum was collected by centrifugation and frozen at -80oC until analyzed. 
Animals were weighed and abdominal fat pads were removed and weighed. Extracted tissues 
and carcasses were immediately frozen in liquid nitrogen and stored at -80°C prior to RNA 
extraction and immuno-histochemical analysis. All experimental protocols for animal care 
and use were approved by the Institutional Animal Care and Use Committee at Iowa State 
University, Ames, IA, USA. 
Analysis of metabolic parameters. Blood glucose, total cholesterol, and 
triacylglycerides (TAG) were measured using CardioChek P•A ® system (Polymer 
Technology Systems, Inc.). Serum insulin (Linco), C-reactive protein (CRP) (Immunology 
Consultants Laboratory, Inc.), and MCP-1 (R&D Systems) were measured using commercial 
assay kits. Non-esterified fatty acids (NEFA) were measured with NEFA-C kit (Wako Pure 
Chemical Industries, Inc.). Serum endotoxin determinations were performed using a kit 
based upon a Limulus amaebocyte extract (LAL kit; Hycult Biotechnology). Samples were 
diluted 1:40. Internal control of recovery calculation was included in the assessment. 
Quantitative real-time PCR. Total RNA was extracted and cDNA synthesized as 
described previously (9). Primer sequences are listed in Table 7. The abundance of each gene 
product was calculated by regressing against the standard curve generated in the same 
reaction with their respective plasmid. All genes of interest were normalized to beta actin and 
expressed as log starting quantity. 
Serum fatty acid profile. Lipid from serum samples were extracted by the method of 
Lepage and Roy (15) with minor modifications as described previously (9).  
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Stromal vascular cell (SVC) isolation and culture. Male Tlr2-/- or 6J mice were 
euthanized by CO2 asphyxiation. Epidydimal fat pads were removed, trimmed, and diced 
before adding to sterile digestion cocktail (1X Krebs Ringer buffer (KRB) and 200 U/ml 
collagenase) for 1 h in 37°C shaking water bath. Inter-phase liquid, absent of floating 
adipocytes and debris, was centrifuged at 800 x g for 4 min. The resulting pellet was 
resuspended in red blood cell lysis buffer (pH 7.2; 155 mM HH4Cl, 5.7 mM K2HPO4, and 0.1 
mM EDTA) for 5-6 min and then diluted with 1X PBS and centrifuged for 800 x g for 15 
min. Following a second PBS wash, the pellet was resuspended in low glucose DMEM 
containing 10% FBS and 5% streptomycin/penicillin mixture. Growth media was changed 
after 4 h and then again at 24 h, after which media was replaced every 48 h. Cells were split 
twice before being frozen in media containing 15% DMSO. These stocks were subsequently 
used for all experiments. 
When cells reached 70-80% confluence, adipocyte differentiation cocktail (growth 
media containing 1.5 mM IBMX, 1.0 µM dexamethasone, 1.7 µM insulin, and 0.4 mM 
biotin) was added for 48 h. Following an additional 48 h with differentiation cocktail, cells 
were cultured in growth media with insulin. At 14 d post-differentiation, approximately 40% 
of SVC exhibited adipocyte phenotype (e.g., lipid accumulation). Cells were then treated 
with 0.5 mM sodium palmitate, 10 µg/mL LPS from Escherichia coli 055:B5, or 20 µg/mL 
ZymA from Saccharomyces cerevisiae for 48 h and used thereafter for analysis of glucose 
uptake. 
2-Deoxyglucose (DG) Uptake. SV cells were treated as described and glucose uptake 
was measured as previously described (16).  
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Statistical analyses. Data were tested for normality and analyzed using the mixed-
model analysis with diet and genotype considered fixed effects, and the time dietary 
treatments were implemented for subgroups as a random effect. Significant interactions of 
main effects are indicated as Diet*Genotype effects.  All indicated P-values were two-tailed 
and Bonferroni corrected. Differences were considered significant at P < 0.05 and a tendency 
at P < 0.10. Values are presented as least squares (LS) means ± SEM.   
Results 
 
Tlr2-/- and 10ScN mice are protected from diet-induced obesity independent of caloric 
intake.  Unlike 10ScN mice, Tlr2-/- mice did not exhibit a reduction in body weight (Fig. 
12A) or weight gain (Fig. 12B) compared to 6J controls (Genotype, P= 0.68). In contrast, 
10ScN mice had on average 2.9 g lower body weight relative to 10J mice (Genotype, 
P=0.0018). This relationship was especially evident in HFP fed 10ScN mice (Diet*Genotype, 
P=0.0076) and is consistent with our previous findings (9). To further evaluate the level of 
adiposity, we measured epidydimal fat pad weight (Fig. 12C) and observed that both Tlr2-/- 
and 10ScN mice had approximately 20% and 30% lower fat pad weight compared to their 
controls, respectively (Genotype, P<0.0001). Epidydimal fat pad weight was higher in high 
fat diet fed mice (Diet Effect, P=0.032) relative to LFC fed mice. These effects on fat pad 
weight were independent of energy intake as there were no intake differences between Tlr2-/- 
and 6J mice (Fig. 12D, Genotype, P=0.58). However, 10ScN mice actually exhibited greater 
energy intake than 10J mice (Genotype, P=0.0097), which was especially evident in HFC fed 
mice (Diet*Genotype, P=0.0007). 
Tlr4 deficiency, but not Tlr2 deficiency, improved markers of insulin sensitivity, 
particularly in mice fed a high saturated fat diet. In the present study, we measured fasting 
  140
blood glucose (Fig. 13A) and serum insulin (Fig. 13B) to determine if Tlr2-/- mice might also 
exhibit modification of insulin sensitivity. We have shown that blood glucose concentration 
was over 10% lower in 10ScN mice versus 10J controls (Genotype, P=0.019). However, we 
observed no significant difference in blood glucose or serum insulin between Tlr2-/- and 6J 
controls (Genotype, P=0.12 and P=0.66, respectively). Dietary treatment also had no effect 
on blood glucose regardless of genotype (Diet, P=0.93). In contrast, serum insulin was 
approximately 30% higher in mice fed HFP compared to HFC (Diet, P=0.035) suggesting 
that a diet rich in SFA is more insulinemic compared to a diet rich in unsaturated FA. One 
caveat to this was that 10ScN mice had a tendency toward lower insulin concentration when 
fed the HFP diet compared to 10J controls (Diet*Genotype, P=0.10).  
Absence of Tlr2 and Tlr4 expression differentially modified markers of systemic 
inflammation. We measured several proinflammatory markers in serum, including CRP (Fig. 
13C), endotoxin (Fig. 13D), and MCP-1 (Fig. 13E). Circulating CRP concentration was 
greater in mice fed a saturated versus unsaturated fat diet (P=0.031), but this effect was 
blunted in Tlr4 deficient mice fed HFP diet (Diet*Genotype, P=0.0034). Furthermore, Tlr4 
deficient mice showed a nearly 30% reduction in serum endotoxin regardless of diet 
(Genotype, P=0.048).  In contrast, there was no detectable difference in serum CRP or 
endotoxin between Tlr2-/- and 6J mice (P=0.46 and P=0.79, respectively). Serum 
concentration of the proinflammatory chemokine, MCP-1, was approximately 55% lower in 
10ScN mice versus 10J controls (Genotype, P=0.0035). The reduction in MCP-1 
concentration was more evident in Tlr4 deficient mice fed either high fat diet 
(Diet*Genotype, P=0.035 (HFC) and P=0.05 (HFP), respectively). Tlr2-/- mice were also 
protected from the HFP diet-induced MCP-1 increase (Diet*Genotype, P=0.0038), but not 
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from the HFC diet (Diet*Genotype, P=0.58). Therefore, it appeared that Tlr2, in addition to 
Tlr4, was involved in the stimulation of the SFA diet-induced serum MCP-1.  
Tlr2 and Tlr4 deficiencies differentially modified circulating lipid profiles in 
response to high fat diets. We measured both the concentration and composition of serum 
lipids in order to determine their relationship with obesity-induced inflammation. We have 
shown that mice fed either high fat diet had a near 20% higher serum total cholesterol (Table 
8, Diet, P=0.0075 (HFC) and P<0.0001 (HFP), respectively), whereas serum TAG (Table 8) 
was elevated in LFC fed mice regardless of genotype (Diet, P< 0.0001). Furthermore, 10ScN 
mice exhibited approximately 20% greater serum TAG compared to 10J controls (Genotype, 
P=0.0049), which was more apparent in 10ScN mice fed LFC diet (Diet*Genotype, 
P<0.0001). Similarly, circulating NEFA (Table 8) were higher in 10ScN mice fed the LFC 
diet (Diet*Genotype, P<0.01). There were no observed differences in serum TAG or NEFA 
between Tlr2-/- mice and 6J controls (Genotype P=0.97 and P=0.85, respectively).  
We next analyzed the composition of serum FA (Table 9). Total SFA, palmitate, and 
stearate content were all 21%, 14%, and 35% higher in serum of mice fed HFP and LFC 
compared to HFC diet, respectively (Diet, P<0.0001). In contrast, total omega-6 and omega-
3 FA content were approximately 18% and 25% greater in serum of mice fed HFC than HFP 
diet (Diet, P<0.0001), which corresponds with higher serum linoleate, α-linolenate, and DHA 
(Diet, P<0.0001). Polyunsaturated FA (PUFA) content was also different between LFC and 
HFP fed mice. Total omega-3 FA was greater in mice fed LFC (Diet, P<0.0001), whereas 
total omega-6 FA was greater in mice fed HFP (Diet, P=0.0029), which is consistent with the 
observed DHA (Diet, P<0.0001) and γ-linoleate concentrations (Diet, P<0.01), respectively. 
Genotype had a minimal impact on FA composition. However, Tlr2-/- mice exhibited higher 
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circulating stearate (Genotype, P=0.0003) with a trend toward an increase in total SFA 
(Genotype, P=0.083) compared to 6J controls. Conversely, 10ScN mice had higher α-
linolenate (Genotype, P=0.0067) and linoleate (Genotype, P=0.0960) versus 10J controls. 
These data indicated that the circulating lipid profile was more closely related to dietary lipid 
content than genotype, thus indicating that the anti-inflammatory effects of Tlr2 or Tlr4 
deficiency were not due to alterations in FA profile. 
Obesity-induced inflammation in adipose tissue was differentially regulated by high 
saturated and unsaturated fat diets, and was partly ameliorated by Tlr2 and Tlr4 deficiency.  
We first confirmed that Tlr4 (Fig. 14A) and Tlr2 (Fig. 14B) gene expression were deficient 
in AT of 10ScN and Tlr2-/- mice, respectively (Genotype, P<0.0001). Transcript abundance 
of Tlr4 was 2-fold greater in mice fed either high fat diet (Diet, P=0.0068 (HFP) and P=0.020 
(HFC), respectively). SFA fed mice also exhibited a 3-fold increase in Tlr2 transcript levels 
compared to LFC diet fed mice (Diet, P=0.0009).  
To determine whether Tlr2 or Tlr4 deficiency corresponded with changes in 
inflammation, we measured transcript abundance of TNFα (Fig. 14C), IL-6 (Fig. 14D), and 
MCP-1 (Fig. 14E) in AT of Tlr2-/-, 10ScN, and the respective control mice. Tlr2-/- mice had 
2-fold lower TNFα and MCP-1 transcript levels in AT compared to 6J mice (Genotype, 
P<0.0001 and P=0.0087, respectively). Similarly, TNFα transcript abundance was 2-fold 
lower in 10ScN mice versus 10J controls (Genotype, P=0.0269). Tlr2-/- mice were 
specifically protected from HFP diet-induced TNFα, IL-6, and MCP-1 expression in AT 
(Diet*Genotype, P=0.0010, P=0.051, and P<0.0001, respectively). Tlr4 deficiency lowered 
IL-6 and MCP-1 transcript abundance by 2-fold in AT of HFP fed mice (Diet*Genotype, 
P=0.045 and P=0.046). These findings indicated that the ability of a high saturated fat diet to 
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induce expression of proinflammatory cytokines was significantly blunted without either 
functional Tlr2 or Tlr4. 
We have shown that transcript abundance of macrophage marker, F4/80, was over 2-
fold lower in Tlr2-/- and 10ScN mice relative to respective controls (Genotype, P=0.025 and 
P=0.032). Absence of Tlr2, as well as Tlr4, specifically attenuated F4/80 transcript 
abundance in HFP fed mice F4/80 (Diet*Genotype, P=0.0014 and P=0.0045, respectively).  
In the present study, nitric oxide synthase-2 (NOS2) transcript abundance was 5.2- 
and 5.9-fold  lower in both Tlr2-/- and 10ScN mice compared to 6J and 10J controls 
(Genotype, P<0.0001). This effect was more prominent with either high fat diet (Diet, 
P<0.0001), but the highest level of NOS2 transcript was in HFP fed mice (Diet, P=0.030). 
The ability of Tlr2 or Tlr4 deficiency to attenuate HFC-induced NOS2 was similar 
(Diet*Genotype, P<0.0001). However, only 10ScN mice exhibited a protective effect against 
the HFP diet (Diet*Genotype, P<0.0001). Overall, these results indicated that Tlr2 and Tlr4 
were important mediators of macrophage accumulation and oxidative stress in AT of mice 
fed either high fat diet. 
Tlr2 deficient SV cells were protected from FFA-induced inflammation and insulin 
resistance. We observed a limited effect of Tlr2 deficiency on blood glucose and serum 
insulin. These findings may reflect an increased susceptibility to DIO on the 6J background, 
which was clearly demonstrated by the greater body weight, adiposity, and energy intake in 
mice on 6J background (Tlr2-/- and 6J), relative to 10J background (10ScN and 10J) 
(Genotype, P<0.0001). Thus, we investigated if insulin sensitivity in Tlr2-/- mice was 
improved at the cellular level. To do this we isolated and cultured primary SV cells from AT 
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of Tlr2-/- and 6J mice. Confluent cells were then treated with adipocyte differentiation media 
(~40% of cells exhibited lipid accumulation) and used for determination of 2-DG uptake.  
We demonstrated that Tlr2-/- SV cells exhibited greater insulin sensitivity than 6J 
cells, regardless of treatment (Fig. 15, Genotype, P<0.0001). Furthermore, Tlr2 deficient SV 
cells treated with palmitate, LPS, or ZymA for 48 hr had improved insulin sensitivity 
compared to 6J cells (Treatment, P<0.0001). However, only ZymA-induced insulin 
resistance was completely attenuated in Tlr2-/- SV cells compared to insulin-stimulated 
controls (Treatment*Genotype, P<0.0001). The inability of Tlr2 deficiency to fully block 
palmitate mediated insulin resistance indicated an alternative pathway. Tlr4 represents a 
potential candidate, as LPS-induced insulin resistance was unaffected by Tlr2 deficiency 
(Treatment*Genotype, P<0.0001). These data indicated that absence of functional Tlr2 
improved insulin sensitivity in SV cells isolated from AT, but failed to completely block 
SFA-induced insulin resistance due to Tlr2-independent pathways, such as Tlr4. 
Discussion 
 
Obesity is associated with chronic low grade inflammation, which contributes to the 
development of insulin resistance (17). The molecular mechanisms involved are not fully 
elucidated but may involve activation of Tlr2 and Tlr4 signaling pathways in AT. Several 
recent studies (4,6,7,20) have identified a role of Tlr4 in obesity and FA-induced 
inflammation. Herein, we demonstrate that Tlr2-/- mice were protected from DIO without 
significant changes in energy intake or lipid profile. These mice also exhibited a dramatic 
attenuation of systemic and AT inflammation. Moreover, SV cells isolated from AT of Tlr2-/- 
mice had a marked increase in insulin sensitivity. These data indicated that Tlr2 is involved 
in obesity-induced inflammation and insulin resistance. 
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Diets high in SFA are associated with increased inflammation (21). We have 
previously reported that Tlr4 deficiency specifically protected against a high SFA diet-
induced adiposity and inflammation (9). In this study, we confirmed this effect in 10ScN 
mice, but also demonstrated that absence of functional Tlr2 blunted the high SFA diet-
induced inflammation. Moreover, the attenuated inflammatory response in Tlr2-/- and 10ScN 
mice suggests that the absence of these receptors protects against the elevated serum SFA 
observed in HFP-fed control mice. The ability of SFA to induce inflammation through Tlr4 is 
well documented in vitro (5,22). However, only a few studies (12,23) have implicated Tlr2 as 
a potential target for SFA, including Senn (23), who reported that Tlr2 siRNA  reversed 
palmitate-induced activation of IKKβ/NFκB in C2C12 myotubes. These data herein confirm 
the idea  that Tlr2 is an endogenous target for SFA, and thus promotes obesity-induced 
inflammation.  
AT inflammation, as evidenced by macrophage infiltration and proinflammatory gene 
expression, contributes to the development of insulin resistance (17,18). Impaired insulin 
signaling in AT often precedes the onset of systemic insulin resistance (24). We previously 
reported that Tlr4 deficient mice exhibited lower macrophage infiltration in AT (9). In the 
present study, we observed that transcript abundance of the macrophage specific marker, 
F4/80 was markedly reduced in Tlr2 and Tlr4 deficient mice. This reduction was more 
apparent in HFP-fed mice, and corresponded with lower expression levels of multiple 
proinflammatory genes (e.g. TNFα, IL-6, and MCP-1). Additionally, the high fat diet-
induced NOS2 transcript was reduced in Tlr2-/- and 10ScN mice, which supports our 
previous findings that Tlr2 and Tlr4 ligands induce ROS in 3T3-L1 adipocytes (16). Thus, 
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Tlr2 and Tlr4 deficiency protected against AT inflammation and oxidative stress, especially 
when fed a high SFA diet. 
Several investigations (4,6-8) reported Tlr4 involvement in obesity and FA-induced 
insulin resistance. Alternatively, Caricilli et al. (25) showed that injection of Tlr2 antisense 
oligonuleotide attenuated insulin resistance as measured by an insulin tolerance test. 
Furthermore, inhibition of Tlr2 also improved insulin sensitivity in AT and muscle of DIO 
mice. Our data showed that only 10ScN mice exhibited improved serum markers of insulin 
sensitivity. However, to determine if insulin sensitivity was improved in AT, we studied 
insulin sensitivity in primary SV cells from Tlr2-/- mice. Although we observed a marked 
improvement in insulin sensitivity in the Tlr2-/- mice, the absence of Tlr2 failed to fully 
protect against palmitate-induced insulin resistance. These findings indicate that Tlr2 does 
mediated AT specific inflammation, and may be as involved in obesity-induced insulin 
resistance as is Tlr4.  In summary, our study demonstrates a requisite role of Tlr2 and Tlr4 in 
obesity-induced inflammation and insulin resistance. The absence of these receptors protects 
against systemic and AT specific inflammation, especially in mice fed a high SFA diet. We 
therefore assert that both Tlr2 and Tlr4 represent potential dietary and pharmaceutical targets 
for reducing inflammation and insulin resistance associated with obesity. 
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Table 6.  Diet Composition 
Ingredient   Low-Fat Control (LFC)1 High-Fat Control (HFC)1 High-Fat Palmitate (HFP)1 
 
________________________ g/kg_______________________________  
Casein2   140    196    196 
Sucrose2   100    100    100 
Corn Starch2  455.692    88.192    88.192 
Maltodextrin2  155    155    155 
Soybean Oil2  50    360  
     Saturated  7.2    51.9  
          Palmitate  5.2    37.1  
     MUFA  11.7    83.9  
     PUFA  28.9    208.1  
Lard2           235 
     Saturated          92.2 
          Palmitate          55.9 
     MUFA          106 
     PUFA          26.4 
Palmitate3          125 
Cholesterol2      1.5    1.5 
Cellulose2  50    50    50 
Vitamin Mix2  10    10    10 
Mineral Mix2  35    35    35 
Choline Bitartrate2 2.5    2.5    2.5 
L-Cysteine2  1.8    1.8    1.8 
THBQ2   0.008    0.008    0.008 
Total (g)  1000    1000    1000 
Protein (kcal)  567.2    791.2    791.2 CHO (kcal)  2842.768   1372.768   1372.768 
Fat (kcal)  450    3240    3240 
Saturated (kcal)  64.8    467.1    1954.8 
Palmitate (kcal)  46.8    333.9    1628.1 
MUFA (kcal)  105.3    755.1    954 
PUFA (kcal)  260.1    1872.9    237.6 
Density (kcal/g)  3.86    5.40    5.40 
1. Adapted from AIN-93M Diet    2. Harlan Teklad, Madison, WI"    
3. Nu-Check Prep, Inc., Elysian, MN"  
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Table 7.  Primer sequences for quantitative real-time polymerase chain reaction 
 
Target  Forward Primer    Reverse Primer   
 
Beta-Actin  TGAGAGGGAAATCGTGCGTGACAT    ACCGCTCGTTGCCAATAGTGATGA 
Tlr2  TCCCTTGACATCAGCAGGAACACT   GCAGCCGAGGCAAGAACAAAGAAA 
Tlr4  CCGCTCTGGCATCATCTTCATTGT TCCTCCCATTCCAGGTAGGTGTTT 
MCP-1  CCAAGAAGGAATGGGTCCAGACAT ACAGAAGTGCTTGAGGTGGTTGTG 
TNF-α  CCAACGGCATGGATCTCAAAGACA AGATAGCAAATCGGCTGACGGTGT 
IL-6  TCCAGTTGCCTTCTTGGGACTGAT AGCCTCCGACTTGTGAAGTGGTAT 
NOS2  TCTTTGACGCTCGGAACTGTAGCA CGACCTGATGTTGCCATTGTTGGT 
F4/80+  TGCCACAACACTCTCGGAAGCTAT TCCTGGAGCACTCATCCACATCTT 
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Table 8.  Lipid profiles in Tlr2 and Tlr4 deficient mice and wild type controls fed LFC, HFC, 
or HFP diet for 16 weeks 
 
Genotype  Diet        Serum       Serum      Serum 
    Cholesterol                   Triacylglyceride       NEFA 
 
________________________mmol/L______________________ 
10ScN       LFC         5.00 ± 0.59c          1.53 ± 0.08a       2.48 ± 0.29a 
10ScN       HFC        6.39 ± 0.53bc         0.73 ± 0.07c       1.51 ± 0.30b 
10ScN       HFP        6.17 ± 0.51bc          0.75 ± 0.07bc       1.48 ± 0.39b 
 
10J             LFC        5.41 ± 0.63c         0.96 ± 0.09b       1.65 ± 0.32b 
10J             HFC        5.18 ± 0.63c         0.71 ± 0.09c       1.38 ± 0.28b 
10J             HFP                     6.75 ± 0.63b         0.75 ± 0.09bc       1.30 ± 0.35b 
 
Tlr2-/-         LFC        6.69 ± 0.54b         0.92 ± 0.08bc       1.84 ± 0.27ab 
Tlr2-/-         HFC        9.20 ± 0.69a         0.76 ± 0.09c       2.02 ± 0.27a 
Tlr2-/-         HFP                      8.46 ± 0.67a          0.92 ± 0.09bc       2.33 ± 0.32a 
 
6J               LFC        6.23 ± 0.64bc         1.01 ± 0.09b       1.89 ±0.28ab 
6J               HFC        7.07 ± 0.58b          0.69 ± 0.08c         2.08 ± 0.27a 
6J               HFP                     9.02 ± 0.64a          0.92 ± 0.09bc       2.10 ± 0.29a 
 
Main Effects 
Genotype             P < 0.0001         P = 0.0302     P = 0.019 
Diet               P = 0.0001          P < 0.0001      P = 0.36 
Interaction 
Diet*Genotype    P = 0.13          P < 0.0001      P = 0.052 
 
a, b, c, d Significant difference between LS means indicated by different letters (P<0.05) 
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Table 9.  Serum fatty acid profiles in Tlr2 and Tlr4 deficient mice and wild type controls fed 
LFC, HFC, and HFP diet for 16 weeks  
 
a, b, c, d Significant difference between LS means indicated by different letters (P<0.05) 
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Figure 12. Tlr2-/- and 10ScN mice were protected against DIO.  
 
All measures were taken after 16 weeks of LFC (white bars), HFC (black bars), or HFP (grey 
bars) diet (n = 15 unless noted otherwise).  (A) Body weight of 6J, Tlr2-/-, 10ScN, and 10J 
mice (Diet effect P= 0.58, Genotype effect, P<0.0001, Diet*Genotype interaction P=0.0085). 
(B) Total weight gain of 6J, Tlr2-/-, 10ScN, and 10J mice (Diet effect P= 0.58, Genotype 
effect, P<0.0001, Diet*Genotype interaction P=0.0085). (C) Epididymal fat pad weight of 
6J, Tlr2-/-, 10ScN, and 10J mice (Diet effect P=0.032, Genotype effect P<0.0001, 
Diet*Genotype interaction P=0.040). (D) Total energy intake (kcal) of 6J, Tlr2-/-, 10ScN, and 
10J mice (Diet effect P=0.82, Genotype effect P<0.0001, Diet*Genotype interaction 
P=0.013).  All displayed values were adjusted for initial body weight and represent LS means 
± SEM for Diet*Genotype interaction. When main effects (diet and genotype) or interaction 
term were P<0.15, Bonferroni correction was used to determine significant difference 
between means as indicated by different letters.  
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Figure 13. Absence of Tlr2 and Tlr4 expression differentially modified markers of systemic 
insulin sensitivity and inflammation.  
 
All measures were taken after 16 weeks of LFC (white bars), HFC (black bars), or HFP (grey 
bars) diet.  (A) Blood glucose from 6-8 h fasted 6J, Tlr2-/-, 10ScN, and 10J mice (n = 15, Diet 
effect P= 0.81, Genotype effect, P=0.066, Diet*Genotype interaction P=0.65). (B) Serum 
insulin (n = 5, Diet effect P=0.096, Genotype effect P=0.0002, Diet*Genotype interaction 
P=0.15). (C) Serum CRP from 6J, Tlr2-/-, 10ScN, and 10J mice (n = 5, Diet effect P=0.095, 
Genotype effect, P<0.0001, Diet*Genotype interaction P=0.066). (D) Serum endotoxin (n = 
5, Diet effect P=0.57, Genotype effect P<0.0001, Diet*Genotype interaction P=0.34). E) 
Serum MCP-1 (n = 5, Diet effect P=0.42, Genotype effect P=0.0002, Diet*Genotype 
interaction P=0.090). All displayed values were adjusted for initial body weight and 
represent LS means ± SEM for Diet*Genotype interaction.  When main effects (diet and 
genotype) or interaction term were P<0.15, Bonferroni correction was used to determine 
significant difference between means as indicated by different letters.   
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Figure 14. Absence of Tlr2 and Tlr4 expression protected against SFA-induced inflammation 
in AT.  
 
All measures were taken after 16 weeks of LFC (white bars), HFC (black bars), or HFP (grey 
bars) diet.  (A) Tlr4 transcript abundance in AT of 6J, Tlr2-/-, 10ScN, and 10J mice (n = 6, 
Diet effect P=0.014, Genotype effect, P<0.0001, Diet*Genotype interaction P=0.24). (B) 
Tlr2 transcript abundance in AT of 6J, Tlr2-/-, 10ScN, and 10J mice (n = 6, Diet effect 
P=0.0031, Genotype effect P<0.0001, Diet*Genotype interaction P=0.073). (C) TNFα 
transcript abundance in AT of 6J, Tlr2-/-, 10ScN, and 10J mice (n = 6, Diet effect P=0.66, 
Genotype effect P<0.0001, Diet*Genotype interaction P=0.040). (D) IL-6 transcript 
abundance in AT of 6J, Tlr2-/-, 10ScN, and 10J mice (n = 6, Diet effect P=0.34, Genotype 
effect P=0.0005, Diet*Genotype interaction P=0.015). (E) MCP-1 transcript abundance in 
AT of 6J, Tlr2-/-, 10ScN, and 10J mice (n = 6, Diet effect P=0.13, Genotype effect P<0.0001, 
Diet*Genotype interaction P=0.14). (F) F4/80 transcript abundance in AT of 6J, Tlr2-/-, 
10ScN, and 10J mice (n = 6, Diet effect P=0.19, Genotype effect P<0.0001, Diet*Genotype 
interaction P=0.084). (G) NOS2 transcript abundance in AT of 6J, Tlr2-/-, 10ScN, and 10J 
mice (n = 6, Diet effect P<0.0001, Genotype effect P<0.0001, Diet*Genotype interaction 
P<0.0001). All displayed values were adjusted for initial body weight and beta actin 
transcript level. Values represent LS means ± SEM for Diet*Genotype interaction. When 
main effects (diet and genotype) or interaction term were P<0.15, Bonferroni correction was 
used to determine significant difference between means as indicated by different letters. 
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Figure 15. SV cells isolated from Tlr2-/- exhibit improved insulin sensitivity, but were not 
fully protected against FA-induced insulin resistance.  
 
14 d post-differentiated SV cells, in which approximately 40% exhibited an adipocyte 
phenotype (e.g. lipid accumulation), were treated with 0.5 mM sodium palmitate, 10 µg/mL 
LPS, or 20 µg/mL ZymA for 48 h. Insulin-stimulated 2-DG uptake was then determined (n = 
6-8, Treatment effect P<0.0001, Genotype effect P<0.0001, Treatment*Diet effect 
P=0.0007).  A non-insulin stimulated control was included for reference. Results are 
expressed as fold change versus insulin stimulated 6J control and represent LS means ± 
SEM. When Treatment effect was significant (P<0.05), post-hoc t-test was used to determine 
significant difference between LS means as indicated by different letters. 
  158
CHAPTER 6.  SUMMARY 
 
The rise in obesity corresponds to the development of DM and CVD (1,2). The 
molecular mechanism linking obesity to these inflammatory diseases is not fully elucidated 
but may involve AT-specific inflammation (3). Adipocyte hypertrophy is associated 
increased release of proinflammatory cytokines, as well as accumulation of macrophages in 
AT (4,5). Corresponding to obesity-induced inflammation is an increased release of FFA 
from adipocytes, which signals neighboring or downstream cells (6). The ability of FFA, 
especially SFA, to mediate inflammation may be dependent on the presence of specific 
innate immune receptors, Tlr2 and Tlr4. Several studies (7-9) have implicated the 
involvement of these receptors in the development of inflammation and insulin resistance in 
various cell populations. However, little is known about the relationship of these receptors in 
DIO, more specifically, the role of AT inflammation in the development of systemic 
inflammation and insulin resistance. 
We demonstrated that 10ScN mice, with a 74 kb deletion from chromosome 4 that 
precludes expression of Tlr4, were protected against DIO. This effect was more prominent in 
mice fed a high SFA diet. Moreover, these mice exhibited a specific reduction in AT 
inflammation as evidenced by the reduction in proinflammatory transcription factor 
activation and subsequent gene expression. There was also a decrease in macrophage 
accumulation in AT of mice fed the HFP diet. These data indicated that Tlr4 was involved in 
high fat diet-induced adiposity and inflammation in AT. However, Tlr4 deficiency did not 
fully attenuate TNFα and IL-6 transcript abundance in AT of high saturated diet fed mice. 
Corresponding to these findings was an increase in Tlr2 expression, which because of its 
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ability to recognize SFA, represented an additional mechanism mediating obesity-induced 
inflammation. 
To determine involvement of Tlr2 in AT inflammation, we then utilized 3T3-L1 
adipocytes to investigate the ability of the Tlr2 agonist, ZymA, to mediate inflammation and 
insulin resistance. Our data showed that ZymA induced proinflammatory gene expression 
similarly to palmitate and LPS treatment. Furthermore, the Tlr2 agonist stimulated NFκB 
nuclear translocation, although not to the same extent as the Tlr4 agonist, LPS. We also 
demonstrated for the first time in adipocytes that ZymA caused nuclear translocation of the 
proinflammatory transcription factor, AP-1. Thus, Tlr2 involvement in adipocyte 
inflammation was apparent. Along with the proinflammatory response observed with ZymA, 
LPS, and palmitate treated cells was an increased accumulation of ROS, which closely 
paralleled expression of NOS2 transcript abundance. The ability of inflammation and 
oxidative stress to mediate insulin resistance is well documented (6,10,11). Therefore, we 
evaluated insulin-stimulated glucose uptake in adipocytes treated with SFA or Tlr agonist 
and showed a significant reduction in insulin sensitivity with these treatments.  
Activation of the intracellular kinase, JNK, is associated with Tlr signaling (7,12) 
thus, we investigated the ability of a highly specific JNK inhibitor to reduce inflammation 
and oxidative stress, as well as improve insulin sensitivity. There was a marked attenuation 
of insulin resistance in ZymA, LPS, and palmitate treated adipocytes, which corresponded to 
a reduction in NFκB and AP-1 activation, proinflammatory gene expression, and ROS 
accumulation. From these data we concluded that Tlr2 is likely involved in obesity-induced 
inflammation and oxidative stress in AT, as well as insulin resistance in adipocytes. 
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Additionally, it appeared that JNK activation was essential to the SFA and Tlr agonist 
mediated effects. 
 Based on our studies with Tlr4 deficient mice and cultured adipocytes, we then 
investigated the role of Tlr2 in obesity-induced inflammation and insulin resistance. 
Moreover, we wanted to determine whether the dietary source of FA (saturated vs. 
unsaturated) differentially modified inflammation and insulin resistance. Our data showed 
that Tlr2-/- mice were protected from DIO. However, unlike Tlr4 deficient 10ScN mice, there 
were no significant changes in body weight, energy intake, or lipid profile. These findings 
indicated that Tlr2 deficiency significantly modified body composition, which may reflect 
metabolic changes in energy metabolism. For instance, reduced adiposity in Tlr2-/- mice 
associated with energy uncoupling could mediate lower AT accumulation.  
We also demonstrated that serum markers of inflammation, including CRP, 
endotoxin, and MCP-1 were lower in 10ScN mice fed a HFP diet, whereas only MCP-1 was 
reduced in the Tlr2-/- mice fed a high fat diet. The disparity in these data may be due to 
distinct genetic differences in background strain. The 6J background is more susceptible to 
DIO, which in our studies was indicated by higher body weight and adiposity compared to 
mice on 10J background. Therefore, the higher propensity toward obesity in Tlr2-/- mice may 
mask potential changes in markers of systemic inflammation. Despite differences in 
background, both Tlr2 and Tlr4 deficiency improved AT markers of inflammation and 
oxidative stress including TNFα, IL-6, MCP-1, F4/80, and NOS2 transcript abundance. 
Similar to our previous findings, the protective effect of Tlr deficiency was more apparent in 
mice fed the high SFA diet. In Tlr2-/- mice, attenuation of AT inflammation did not correlate 
with improved circulating glucose or insulin concentration. However, SV cells isolated from 
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AT of Tlr2-/- mice had a marked increase in insulin sensitivity, demonstrating the potential 
involvement of Tlr2 in obesity-induced inflammation and insulin resistance. 
The ability of both Tlr2 and Tlr4 to recognize FA and initiate proinflammatory 
signaling in adipocytes, and other cell types, demonstrated the tremendous overlap of 
inflammatory pathways. In order to completely understand the importance of these receptors 
in obesity and FA-induced inflammation, it will be necessary to target each receptor 
simultaneously either with siRNA or generation of double knockout mice. Furthermore, to 
fully elucidate the impact of Tlr2 and Tlr4 on adiposity and insulin resistance, energy 
expenditure will need to be evaluated, as well as more sensitive measures of insulin 
sensitivity, such as the euglycemic-hyperinsulinemic clamp. Our studies also demonstrated 
that Tlr2-/- and 10ScN mice had a greater protective effect when fed diet high SFA. 
Therefore, future studies need to address the ability of various FA to induce an inflammatory 
response through Tlr2 and Tlr4. 
Overall, we have presented evidence that Tlr2 and Tlr4 were involved in obesity-
induced inflammation, as well as insulin resistance. Furthermore, the absence of these 
receptors in AT attenuated inflammation, oxidative stress, and insulin resistance at the 
cellular level (i.e., adipocytes), which in turn reduced systemic inflammation and insulin 
resistance. The underlying mechanism involved recognition of specific FA by Tlr2 and Tlr4, 
and more specifically interaction with SFA. Based on these studies, Tlr2 and Tlr4 may 
represent ideal targets for pharmaceutical, as well as dietary, intervention designed to 
attenuate obesity and related co-morbidities, including DM and CVD. 
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